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ABSTRACT 
South Africa has the largest HIV-infected population in the world, with 
2015 estimates of 7 million people living with HIV and 180,000 AIDS-related 
deaths. The South African government began scale-up of a public-sector HIV 
care and treatment program in 2004, and by the end of 2015, 3.4 million HIV-
infected individuals were on antiretroviral therapy (ART).  
When scale-up began in South Africa, ART was only available to HIV-
infected individuals with CD4 counts ≤200 cells/µL or WHO clinical stage 4 
disease. In 2010, treatment was extended to patients who were pregnant or who 
had tuberculosis and a CD4 ≤350 cells/µL, and in 2011, eligibility was extended 
to all patients with CD4 ≤350 cells/µL. In 2013 patients with WHO clinical stage 3 
disease became eligible. In 2015, the eligibility threshold was increased to CD4 
≤500 cells/µL, and in 2016, the South African National Department of Health 
announced that the country would implement a “test and treat” strategy, offering 
free ART to all HIV-infected individuals, regardless of CD4 count. 
This dissertation examines the effectiveness of several expansions and 
modifications to South Africa’s treatment program. In study 1, we investigated 
 vii 
 
whether the 2011 extension of HIV treatment to patients with CD4 counts ≤350 
cells/µL successfully increased the number of newly-eligible patients on 
treatment (those with CD4 counts between 201–350 cells/µL) without crowding 
out previously-eligible patients with more severe disease (CD4 counts ≤200 
cells/µL), focusing on a network of rural clinics in KwaZulu-Natal. We found 
encouraging results, with newly-eligible patients (CD4 201–350) initiating 
treatment at a greater frequency (73.0 additional patients per month; 95% CI: 
42.1; 103.9) and 47% faster than before (95% CI: 19%; 82%), while previously 
eligible patients (CD4 ≤200) experienced no decline in the number of patients 
initiating treatment or the speed of treatment uptake. 
In study 2, we evaluated whether the introduction of a single-pill fixed-
dose combination (FDC) treatment for ART initiators in South Africa had an 
impact on attrition from care compared to the previously-recommended multiple-
pill regimen. We focused on an urban clinic in Johannesburg, using four different 
clinic attendance measures to define attrition (generally a combined measure of 
loss to follow-up and mortality). An intention-to-treat analysis revealed an 
estimated 11.3 percentage point decrease in attrition (95% CI: -22.0; -0.6) 
associated with the policy change, while a regression discontinuity analysis 
estimated an 18.0 percentage point drop in attrition (95% CI: -33.6; -2.4) 
associated with single-pill FDC treatment relative to multiple pills, controlling for 
unmeasured confounding.  
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In study 3, we used stratified instrumental variable analysis to examine 
whether the effect of FDCs on attrition varied across subsets of the patient 
population in the same Johannesburg clinic we evaluated in study 2. We saw 
larger effects among women (RD -0.25; 95% CI: -0.42; -0.09), non-anemic 
patients (RD -0.24; 95% CI: -0.41; -0.08), patients with early-stage (as opposed 
to advanced) clinical disease (RD -0.20; 95% CI: -0.32; -0.07), and those with 
high CD4 counts (for CD4 ≥350 cells/µL, RD -0.58; 95% CI: -1.58; 0.42). These 
results suggest that healthier patients saw the greatest improvement in retention 
in care following the switch from multiple-pill to single-pill regimens. In an era 
where the healthiest HIV-infected patients are now being targeted for ART 
treatment, FDCs can play a large role in preventing attrition from care. 
These three studies depict an HIV program that has successfully grown to 
treat increasing numbers of patients using up-to-date strategies of care. Given 
the immense scale and cost of South Africa’s HIV treatment program, it is 
important to continue to monitor its effectiveness, especially as it introduces new 
treatments and strategies and adapts to the changing epidemic. 
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INTRODUCTION 
South Africa has been particularly hard hit by the HIV/AIDS epidemic. 
While HIV prevalence in South Africa exploded in the late 1990s, it was not until 
2004 that the country successfully scaled up its public-sector HIV care and 
treatment program. Since that time, the program has been updated regularly, 
largely in concert with recommendations from the World Health Organization 
(WHO). The WHO, recognizing that the western model of specialist physician 
management and advanced laboratory resources is not feasible in much of the 
world, proposed standardized treatment protocols, decentralized service delivery, 
and free provision of treatment in resource-limited settings [1,2]. Today, 
antiretroviral therapy (ART) is available to all HIV-infected individuals in South 
Africa. Despite this incredible progress, South Africa currently has approximately 
7 million people living with HIV [3], the largest HIV-infected population in the 
world. 
When South Africa initially began to scale up public-sector treatment 
access in 2004, ART was only available to HIV-infected individuals with CD4 
counts ≤200 cells/µL or WHO clinical stage 4 disease [4]. In 2011, treatment was 
extended to all patients with CD4 ≤350 cells/µL [5], in 2013, patients with WHO 
clinical stage 3 disease became eligible [6], and in 2015, the eligibility threshold 
was increased to CD4 ≤500 cells/µL [7]. In 2016, the South African National 
Department of Health announced that the country would implement a “test and 
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treat” strategy, offering free ART to all HIV-infected individuals, regardless of 
CD4 count [8].  
 
2011 Extension of ART to Patients with CD4 ≤350 cells/µL  
The 2011 policy change extending treatment to all patients with CD4 
counts of 201–350 cells/µL was estimated to have increased the ART-eligible 
population in South Africa by 900,000 individuals, or 51% [9]. Several clinical 
trials and observational studies had found that earlier ART initiation for patients in 
this CD4 range decreases rates of death, disease progression, and incident 
tuberculosis, while increasing retention in care and virologic suppression [10–16]. 
However, to our knowledge, no study has evaluated the impact of large ART 
eligibility expansions on engagement in care and treatment initiation among 
previously eligible patients with CD4 counts ≤200 cells/µL. If untreated, these 
patients with more severe disease have the highest risks of mortality and 
secondary transmission [17–19]. The benefits of earlier ART initiation must be 
weighed against the possibility that a large influx of patients could overwhelm a 
resource-limited health system, crowding out sicker patients and reducing quality 
of care for all.  
 
2013 Recommendation: Fixed-Dose Combination for First-Line ART 
 In 2013, South Africa adopted the WHO recommendation to use single-pill 
fixed-dose combination (FDC) treatment for first-line ART into its national 
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treatment guidelines [6], replacing several recommended once-daily multiple-pill 
regimens. FDCs are recommended by the WHO for first-line HIV treatment 
because of their potential to improve adherence and retention, as well as their 
lower cost and easier supply, storage, and distribution [20]. 
While South Africa has more patients on ART compared to any other 
country [21], retention in care continues to be a problem, with only 48.3% 
retention estimated at 60 months [22]. ART has extended the life expectancy and 
improved the quality of life for infected individuals, but HIV still requires lifelong, 
frequent medical attention and daily medication adherence. Failure to adhere to 
treatment or attend clinic visits diminishes the personal and population-level 
benefits of HIV control, putting patients at increased risk of antiretroviral 
resistance [23,24], hospitalization [25,26], and mortality [27–29], and increasing 
the risk of secondary transmission [30].  
Several studies have suggested that treatment fatigue resulting from high 
pill burden might reduce a patient’s likelihood of long term ART adherence 
[31,32]. Regimen simplification in the form of fewer doses per day or fewer pills 
per dose has been used to improve treatment adherence for both infectious [33–
35] and chronic [36–38] diseases. Adherence to single-pill ART was higher than 
adherence to multiple-pill regimens in clinical trials of HIV treatment in North 
America, Europe, and Australia [39–41], but when comparing once-daily 
treatments, the single-pill treatment sometimes improved adherence [42–44] and 
sometimes did not [45,46]. We are not aware of any observational studies 
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evaluating differences in retention or adherence for once-daily multiple-pill versus 
single-pill regimens in resource-limited countries. 
A number of factors are known to increase the risk of attrition from care 
among adults on HIV treatment in southern Africa, including patient 
characteristics such as lower CD4 count [47–50], male sex [47,48,51,52], and 
higher WHO stage [47,53] as well as patient experience with care, including 
satisfaction with health services [54] and access to treatment [54–56]. If FDCs 
have an impact on adherence to ART and retention in care, it is likely to differ 
across patient populations. This heterogeneity is especially important to examine 
at this juncture, where healthier patients are increasingly entering HIV care in 
South Africa. 
This dissertation examines the impact of South Africa’s HIV treatment policy 
changes, using the abrupt shifts in practice as natural experiments to compare 
similar populations before and after each change. Study 1 looks at the 2011 
extension of free ART to patients with CD4 levels up to 350 cells/µL, assessing 
whether newly eligible patients did indeed begin treatment, and whether this 
crowded out the sicker, previously-eligible patients. Study 2 focuses on the 
introduction of FDCs as recommended first-line treatment and evaluates whether 
this single-pill treatment led to changes in retention in care. Study 3 more deeply 
explores the impact of FDCs, assessing whether changes in retention were 
heterogeneous across subsets of the patient population. 
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STUDY 1 
Do ART eligibility expansions crowd out the sickest?  
Evidence from rural South Africa. 
 
Introduction 
In September 2015, the World Health Organization (WHO) revised its 
antiretroviral therapy (ART) treatment guidelines, calling for a “test and treat” 
strategy, which extended treatment eligibility to all people diagnosed with HIV 
regardless of CD4 count. This recommendation reversed earlier guidelines that 
limited treatment to patients with lower CD4 counts or severe illness [57]. 
Although expanding eligibility is expected to reduce morbidity, mortality, and 
transmission among patients with high CD4 [11,12,58–62], it is possible that a 
large influx of newly eligible patients in a resource-limited health system could 
crowd out sicker patients and reduce quality of care for all patients, thereby 
mitigating or even reversing the benefits of the expansion. As of September 
2016, South Africa has joined three other countries in sub-Saharan Africa in 
adopting the WHO “test and treat” policy [8,63], and other resource-limited 
countries are also considering expanding eligibility [64,65]. To assess the 
potential for negative spillover effects, we evaluated whether the largest previous 
eligibility expansion in South Africa affected entry into care and ART uptake 
among the sickest patients, whose eligibility was not affected but who were 
exposed to clinic congestion as a result of the guideline change. 
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South Africa has the largest HIV-infected population in the world, with 
2015 estimates of 7 million people living with HIV, and over 3.3 million receiving 
ART [3]. In August 2011, South Africa’s National Department of Health extended 
ART eligibility to all adults with CD4 count ≤350 cells/μL [66], as recommended 
by the WHO 2010 guidelines [67]. Prior guidelines limited eligibility to patients 
with CD4 count ≤200 cells/μL and to pregnant or tuberculosis-infected patients 
with counts ≤350 cells/μL. The 2011 policy change was estimated to have 
increased the ART-eligible population in South Africa by 900,000 individuals, or 
51% [9]. If the resulting clinic congestion led to delays in treatment initiation or 
failure to treat some patients entirely, the consequences would likely be 
particularly dire for patients with the lowest CD4 counts, who have the highest 
risk of mortality between HIV testing and treatment initiation [68–70]. Modeling 
has shown that an extended treatment delay among these patients, which 
increases the risks of secondary transmission and mortality, could theoretically 
lead to a decline in population health even as overall numbers on treatment 
increase [71,72]. 
Several studies have found that earlier ART initiation for patients with CD4 
between 200 and 350 decreases the rates of death, disease progression, and 
incident tuberculosis, while increasing retention in care and virologic 
suppression, among newly eligible patients in both trial [61,73] and non-trial 
settings [12,14–16,74,75]. However, to our knowledge, no study has evaluated 
the causal impact of large ART eligibility expansions on previously eligible 
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patients. One study in Rwanda found an increase in the median CD4 count 
among patients enrolling in care following extension of ART eligibility to all 
patients with CD4 ≤350 cells/μL, but did not examine the specific impact on the 
sickest patients [76]. Another study in rural KwaZulu-Natal, South Africa, found 
that treatment initiation within three months of first clinic visit did not change for 
the sickest patients after this guideline change [77], however, this analysis did 
not control for long-term secular trends. While crowd-out effects seem plausible 
under a test-and-treat approach, there is no evidence to support this notion, even 
from previous guideline changes. 
To evaluate the potential spillover effects of eligibility expansions, we 
assessed whether South Africa’s August 2011 eligibility expansion from a CD4 
≤200 to CD4 ≤350 cells/μL led to changes in care-seeking and ART uptake in 
three groups of patients: those who became eligible under the guideline change 
(CD4 201–350), the sickest who were eligible both before and after the guideline 
change (CD4 ≤200), and those who were not eligible by CD4 count either before 
or after the guideline change (CD4 >350). In all analyses, we use interrupted time 
series methods, which adjust for long run trends.  
 
Methods 
Study Design and Data 
We conducted an observational cohort study using data from the Hlabisa 
HIV Treatment and Care Programme located in KwaZulu-Natal, South Africa. 
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The Hlabisa program was initiated in 2004 as part of a public sector roll-out of 
HIV treatment in South Africa, implemented as a joint initiative by the Department 
of Health and the Africa Health Research Institute (formerly the Africa Centre for 
Population Health). This program includes 17 primary health care clinics 
throughout the Hlabisa sub-district that provide HIV rapid testing, counseling, and 
free ART for those who are eligible under national treatment guidelines [78]. The 
program serves an estimated 228,000 people [79] in a poor, predominantly rural 
area where adult HIV prevalence was about 29% in 2011 [80]. The cohort covers 
the entire sub-district health system and is the primary source of HIV care and 
treatment for residents of this area. 
Any individual who attends a Hlabisa clinic and tests HIV-positive has a 
blood sample drawn for CD4 testing. That same day, the sample is transported to 
the district hospital lab for analysis, and the patient schedules a follow-up visit at 
the local clinic for the following week to learn his or her CD4 results. ART 
eligibility, assessed according to the South African national guidelines, has 
changed over time: CD4 ≤200 cells/μL or WHO stage IV from 2004 [4]; 
expansion to people with CD4 ≤350 cells/μL if tuberculosis-infected or pregnant 
in April 2010 [81]; all adults with CD4 ≤350 cells/μL in August 2011 [5]; all adults 
with CD4 ≤500 cells/μL in January 2015 [7]; and universal treatment regardless 
of CD4 count in September 2016 [8]. Before initiating ART, patients attend three 
ART literacy sessions within a two-week period unless their health status 
qualifies them for fast-tracked treatment initiation. Individuals not yet eligible for 
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ART are encouraged to return to the clinic every six months for monitoring. 
Through linkage with the National Health Laboratory Service, the Hlabisa 
program keeps electronic records for all patients from the time of first CD4 count 
(facility-based HIV diagnosis) rather than from the time of ART initiation. Data on 
sex, age, visit dates, CD4 test results, and date of transfer to another clinic 
(where applicable, if known) are recorded for all patients. Additional data are 
available for patients who initiate ART, including clinical information, pregnancy 
and tuberculosis status, and routine lab results. 
This secondary analysis of de-identified data was determined to be "not 
human subjects research" by the Boston University Medical Campus Institutional 
Review Board (protocol H-35385).  
 
Outcomes and Exposures 
We evaluated four outcomes to assess changes in clinic burden and 
treatment initiation in the period before compared to the period after the August 
2011 ART eligibility expansion: (1) monthly number of new HIV diagnoses; (2) 
monthly number of patients initiating ART; (3) monthly proportion of new patients 
who initiate ART within six months; and (4) days from first clinic visit to treatment 
initiation. Our analyses include all adults ≥16 years old who sought care in the 
public sector between April 1, 2010, when the previous guideline change was 
implemented, and June 31, 2012, six months prior to completion of data 
collection. Outcomes 1 and 2, the numbers of patients entering care and initiating 
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ART, arise from an unobserved reference population of persons in need of HIV 
care residing in the Hlabisa catchment area. We use time series models to allow 
for smooth secular changes in this implicit denominator. Outcomes 3 and 4 were 
defined only for HIV-diagnosed patients who had a CD4 blood sample drawn. 
Patients were included in these analyses regardless of ART eligibility. We 
excluded a small number of patients whose ART initiation date preceded their 
first reported visit to the Hlabisa clinics or who were missing results for their first 
CD4 test.  
All analyses were stratified by CD4 count at the time of facility-based HIV 
diagnosis. We defined patients with CD4 ≤200 cells/μL as “always eligible” (as 
they would have been eligible for ART initiation under the 2010 guidelines), 
patients with CD4 201–350 cells/μL as “newly CD4-eligible” (as they would not 
have been eligible until 2011 without another condition), and those with CD4 
>350 cells/μL as “never CD4-eligible” (as they would not have been eligible 
before or after the 2011 expansion without another condition). Because CD4 
counts were not the sole determinant of ART eligibility, we would expect a slightly 
diminished effect of the August 2011 expansion among the “newly CD4-eligible” 
if any patients were previously eligible due to other conditions. This other 
eligibility criterion would not have affected the “always eligible” population. 
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Statistical analysis 
To describe trends in new patient volume and new ART initiator volume, 
we report the mean monthly count of new HIV diagnoses and new initiators 
before versus after the policy expansion. To estimate the impact of the reform on 
(1) numbers seeking care, (2) numbers starting ART, and (3) the proportion of 
patients who initiated ART within six months, we performed linear regression on 
monthly values of these three outcomes as interrupted time series analyses 
controlling for first-order temporal autocorrelation, using patient data from April 
2010 through June 2012. For outcome (3) we excluded individuals whose first six 
months in care overlapped with the eligibility expansion (i.e., first presented in 
March through August 2011) in order to reduce our chances of capturing 
outcomes affected by the expansion for patients diagnosed in the pre-expansion 
period. Thus, our analysis of outcome (3) compared patients diagnosed during a 
pre-period April 2010 through February 2011 with patients diagnosed during a 
post-period September 2011 through June 2012. All regression models include 
the following covariates: a dichotomous indicator taking the value one if 
enrollment in care occurred after August 2011, a continuous “study month” 
variable to capture secular trends, and a dichotomous “holiday” term controlling 
for a known pattern of annual changes in clinic attendance in December and 
January. In alternate models, we added an interaction term between “study 
month” and the post-expansion indicator, allowing for separate time trends on 
either side of August 2011. Under this approach, the post-expansion indicator 
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estimates the impact immediately following the guideline change, rather than the 
average effect across the whole post-expansion period. 
To evaluate the impact of the guideline change on outcome (4), days from 
presentation to treatment initiation, we estimated Cox proportional hazards 
regression models, controlling for all covariates listed above as well as sex and 
age. Person-time was censored at transfer to another clinic outside the Hlabisa 
system or 180 days of follow-up. We report adjusted hazard ratios for the effect 
of presenting for care after the guideline change. Additionally, to assess 
transitions to ART initiation non-parametrically, we estimated Kaplan-Meier 
failure curves, comparing patients presenting for care in the pre and post periods, 
adjusting for “holiday,” age, and sex using inverse probability of treatment 
weighting methods. All analyses were stratified by CD4 count at clinical 
presentation: 0–200, 201–350, >350 cells/μL. 
 
Results 
Study population 
Our study sample included 13,809 patients (after excluding 166 whose 
ART initiation date preceded their first reported visit to the Hlabisa clinics and 16 
without values for first CD4 count). 8,531 patients were included prior to the 
guidelines change as they had their first visit in the sixteen-month period April 1, 
2010 to August 31, 2011, while 5,278 patients were included after eligibility 
expansion as they first presented in the ten-month period September 1, 2011 to 
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June 30, 2012. Patients were predominantly female (68%), with a median age of 
31 years at first presentation (IQR 25 – 39) (Table 1.1).  
At first CD4 count, 5,050 patients (37%) fell into the “always eligible” CD4 
category (≤200 cells/μL), 3,610 (26%) were “newly CD4-eligible” (201–350 
cells/μL) and 5,149 (37%) were “never CD4-eligible” (>350 cells/μL). Overall, 
4,474 patients (32%) initiated ART within six months from first presentation, 
including patients not yet eligible for ART.  
 
Number of Patients Seeking HIV Care  
While eligibility expansion is expected to increase the proportion of 
patients eligible for treatment, it might also impact the number of patients 
presenting to the clinic for HIV testing if they believed they would be more likely 
to access treatment if positive. An average of 501.8 (SD = 77.8) patients 
diagnosed per month before the guideline change increased to 527.8 (SD = 65.6) 
following the guideline change (Table 1.2). This crude change [+26.0; 95% CI     
(-34.5; 86.4)] was measured imprecisely, but controlling for the long-term decline 
in new diagnoses (Figure 1.1) revealed that the policy increased patient 
presentation by 62.7 per month (95% CI: -24.6; 150.0), or 12.5%, relative to 
expectation (Table 1.2). Our adjusted analyses stratified by first CD4 count 
showed an immediate increase in the numbers of “newly CD4-eligible” and 
“never CD4-eligible” patients seeking care following the eligibility expansion 
[+34.1; 95% CI (1.1; 67.1) and +58.8; 95% CI (3.3; 114.4), respectively] (Table 
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1.2). However, these changes did not lead to long-term changes in average 
patient volume (Figure 1.1, Table 1.2). 
 
Number of Patients Initiating ART  
The average number of patients initiating ART per month increased from 
300.5 (SD = 61.9) before the guideline change to 378.5 (SD = 74.2) afterward 
(Table 1.3). Our adjusted linear regression revealed that, because initiation had 
been declining over time, the average monthly increase in new ART initiators 
attributable to the policy change was 95.5 (95% CI: -1.3; 192.3), a 32% increase 
over the adjusted pre-period average (Table 1.3). 
When stratified by first CD4 count, this increase in ART initiation was most 
pronounced among “newly CD4-eligible” patients (CD4 201–350), who averaged 
85.8 (SD = 19.1) initiators per month prior to the guideline change and 142.6 (SD 
= 142.6) afterward, an adjusted increase of 73.0 patients per month [95% CI 
(42.1; 103.9)], or 85% (Table 1.3). We found evidence of a small increase among 
patients with CD4 >350 (“never CD4-eligible”) [adjusted +30.3; 95% CI (-6.9; 
67.6)]. There was no evidence of a decline in the number of monthly ART 
initiators among sicker patients who were always eligible (CD4 ≤200 cells/μL) 
[adjusted +10.6 (95% CI: -28.6; 49.8)]. Figure 1.2 plots trends in number of ART 
initiators by CD4 count.  
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Time from Clinical HIV Diagnosis to ART Initiation 
Because this was conducted in the era prior to treatment for all, monthly 
numbers of ART initiators are the product of two factors: numbers entering care 
(presented above) and rates of progression to ART initiation. The proportion of 
patients who started ART within six months of HIV diagnosis doubled in the 
“newly CD4-eligible” group from 24.3% to 49.9% [+25.6 (95% CI: 22.2; 29.1)] 
when comparing April 2010 through February 2011 versus the ten months 
following the policy change. Among “always eligible” patients (CD4 ≤200), there 
was no evidence of impeded transition to ART, with the proportion initiating within 
six months increasing slightly from 57.9% pre-reform to 63.2% post-reform [crude 
+5.3 percentage points (95% CI: 2.2; 8.4)]. Similarly, the proportion of “never 
CD4-eligible” patients (CD4 >350) who initiated within six months increased 
modestly from 2.9% to 4.3% [crude +1.4 percentage points (95% CI: 0.3; 2.6)] 
(Table 1.4). These findings were confirmed, albeit attenuated, after controlling for 
time trends, with adjusted increases of 4.0 percentage points (95% CI: -2.7; 10.6) 
for the “always eligible,” 5.5 percentage points (95% CI: -8.8; 19.8) for the “newly 
CD4-eligible” and -0.7 percentage points (95% CI: -2.4; 1.3) for the “never CD4-
eligible” categories (Table 1.4). Models of immediate impact, with different slopes 
after the policy change, revealed similar results (Table 1.4). Figure 1.3 plots 
changes in six-month initiation by CD4 count. 
Moving from a binary treatment indicator to a continuous-time survival 
analysis, we estimated adjusted Cox proportional hazards models. The overall 
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speed of ART initiation increased following the guideline change (HR = 1.18; 
95% CI 1.06; 1.33). This increase was strongest among “newly CD4-eligible” 
patients [HR = 1.47; 95% CI (1.19; 1.82)], with possible modest increases among 
the “always eligible” (HR = 1.06; 95% CI 0.92; 1.23) and “never eligible” 
categories (HR = 1.19; 95% CI 0.69; 2.06) (Table 1.5). We found similar results 
when focusing on the period immediately following the policy change (Table 1.5). 
To illustrate the progression of patients from diagnosis to treatment before 
and after the eligibility expansion, Figure 1.4 shows Kaplan-Meier failure curves 
adjusted for holiday, sex, and age (but, notably, not for the underlying time 
trend). The figures reveal four important trends. First, there was a very large 
increase in the proportion initiating ART among “newly CD4-eligible” patients. 
Second, among “always eligible” patients (CD4≤200 cells/μL), there was no 
evidence of inferior outcomes post-expansion; in fact, the proportion initiating 
increased somewhat for this group. Third, among “always eligible” patients who 
initiated ART, time from diagnosis to initiation fell from a median of 40 days (IQR: 
27; 63) to 28.5 days (IQR: 18; 44). Although the sickest patients initiated faster, 
patients in the newly CD4-eligible category progressed to initiation within a time 
frame similar to the sickest pre-reform. Finally, although the reform increased 
initiation, the proportion initiating ART among eligible patients remained relatively 
low. 
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Discussion 
Expanding CD4 eligibility criteria for ART to ≤350 cells/μL at the Hlabisa 
HIV Treatment and Care Programme in rural South Africa resulted in an 85% 
increase in ART initiation among “newly-eligible” patients with CD4 counts 
between 200 and 350 cells/µL and a 32% increase in the number of patients 
initiating ART overall. In spite of this large influx of healthier patients onto ART, 
we found no evidence of crowd out among sicker patients. Clinics successfully 
absorbed the large cohort of newly-eligible patients without adverse impact on 
initiation rates for those in greatest need for ART. In fact, we found evidence that 
ART uptake increased modestly for the sickest patients and times to initiation fell. 
Maintaining the timeliness of treatment is critical, especially for the sickest 
patients, who show the greatest rise in mortality when not treated promptly [68–
70].  
In addition to faster progression from diagnosis to ART initiation, we found 
some evidence that raising CD4 thresholds led to increased care-seeking, at 
least in the short run, a phenomenon that has been reported elsewhere [76]. We 
found the greatest increase in new patients at higher CD4 counts, who would not 
likely have been eligible before the policy change. These results suggest that 
extending treatment eligibility to all HIV-infected individuals could increase the 
proportion of HIV-infected individuals who seek HIV testing, which would in turn 
increase numbers on treatment. The gains in numbers seeking care appeared to 
be short-lived, however, perhaps reflecting publicity around the guideline change 
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or depletion of the pool of untreated eligible individuals after a shift of new 
patients into care. Interestingly, we found no increase in new patients in the 
previously eligible (CD4≤200 cells/μL) category, suggesting that beliefs about the 
probability of being eligible for treatment may be an important factor in HIV 
testing and care-seeking behavior.  
Increasing the number of patients on treatment without compromising 
timeliness of care is a noteworthy achievement and may bode well for the rising 
patient loads anticipated as South Africa implements “test-and-treat.” Indeed, the 
eligibility expansion was implemented successfully in Hlabisa, despite being 
located in one of the poorest districts in South Africa [82], in a predominantly 
rural area with very high HIV prevalence [80]. Several factors may explain our 
findings. First, there may have been more efficient implementation of nurse-
initiated management of ART during this period [83]. Second, clinics fast tracked 
the sickest patients for accelerated initiation and initiated healthier patients on a 
less urgent schedule to make better use of existing resources for the greatest 
potential benefit. These differences can be observed in the reduction in time to 
initiation for patients with CD4≤200 cells/μL pre- versus post-August 2011, as 
well as the shorter time to initiation for patients with CD4≤200 cells/μL relative to 
healthier patients with CD4>200 cells/μL post-August 2011 (Figure 1.4). Further 
research is needed to determine the relative contributions of these factors to the 
capacity to take on more patients, and to determine more precisely the lessons 
for health systems in other settings. 
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Our results should be considered in light of their limitations. We evaluated 
the experience of one system of clinics in one region of South Africa, and our 
results may not generalize to other settings. Our data on ART uptake was 
complete only through December 2012, limiting our post-eligibility expansion 
period to ten months after the guideline change (through June 30, 2012), as our 
outcome of interest was ART initiation within six months. Additionally, time series 
analyses are vulnerable to confounding by unpredictable (and unmodeled) 
secular trends. However, our exclusion of data that would be affected by earlier 
policy changes, our adjustment for changes in clinic operations during the holiday 
season, and our control for gradual changes over time mitigate against such 
biases. Finally, we assessed the spillover effect of the eligibility expansion on 
entry into care and time to ART initiation among patients with lower (previously-
eligible) CD4 counts. However, additional dimensions of quality that were not 
observed in this study would be an important avenue for future research. For 
example, it has been documented that timely switching of ART to second line 
therapy based on viral load failure is suboptimal, possibly because of time 
pressure on clinic staff [84]. 
Our finding that the Hlabisa HIV Treatment and Care Programme 
successfully implemented ART eligibility scale-up without incurring negative 
spillover effects on the sickest patients provides support for the feasibility of 
further program expansion. This particular program can serve as a model for 
scale-up in other rural, resource-limited settings, and should be considered when 
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evaluating the economic costs and implications of ART eligibility expansions. As 
South Africa has now extended treatment to all HIV-infected patients, it will be 
important to continue to monitor the impact of these policies on all patients 
across CD4 levels and throughout the treatment cascade. 
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Table 1.1: Characteristics of patients seeking HIV care in Hlabisa, KwaZulu-Natal, 
South Africa. 
 
 Apr 2010 – 
Aug 2011 
Sept 2011 – 
Jun 2012 
Total 
 (n = 8531) (n = 5278) (n = 13809) 
First CD4 count       
n (%) 
CD4 < 200 3455 (40.5%) 1595 (30.2%) 5050 (36.6%) 
 CD4 200 – 350 2188 (25.6%) 1422 (26.9%) 3610 (26.1%) 
 CD4 > 350 2888 (33.9%) 2261 (42.8%) 5149 (37.3%) 
Started ART 
within 6 months 
Overall 2659 (31.2%) 1815 (34.4%) 4474 (32.4%) 
n (%) CD4 < 200* 2005 (58.0%) 1008 (63.2%) 3013 (59.7%) 
 CD4 200 – 350* 570 (26.1%) 710 (49.9%) 1280 (35.5%) 
 CD4 > 350* 84 (2.9%) 97 (4.3%) 181 (3.5%) 
Female 
n (%) 
 
5784 (67.8%) 3589 (68.0%) 9373 (67.9%) 
History of TB at 
ART initiation 
n (%)** 
 
659 (24.8%) 314 (17.3%) 973 (21.7%) 
Age in years at 
first CD4 count 
median (IQR) 
 
31 (25 – 39) 31 (25 – 39) 31 (25 – 39) 
Age in years at 
ART initiation 
median (IQR) 
 
32 (27 – 40) 32 (26 – 40) 32 (26 – 40) 
* Denominator for % is number of individuals from this category of “First CD4 count.” 
** Denominator for % is number of individuals from this category who initiated ART 
within 6 months. 
ART = antiretroviral therapy; TB = tuberculosis; IQR = interquartile range 
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Table 1.2: Interrupted time series effect estimates of August 2011 eligibility expansion on entry into care among 
patients previously eligible, newly eligible, and not yet eligible.  
CD4 count at 
clinical 
diagnosis 
Mean monthly count of new 
patients 
  
Change in count of new patients 
 
Apr 2010 – 
Aug 2011 
Mean (SD) 
Sept 2011 – 
June 2012 
Mean (SD) 
 Crude change in 
mean 
(95% CI) 
Adjusted change 
in mean* 
(95% CI) 
Adjusted difference 
at the threshold** 
(95% CI) 
Overall 501.8 (77.8) 527.8 (65.6)  26.0 (-34.5; 86.4) 62.7 (-24.6; 150.0) 97.2 (-0.2; 194.6) 
CD4 ≤ 200 203.2 (57.8) 159.5 (28.6)  -43.7 (-84.2; -3.2) 22.5 (-44.6; 89.5) 10.2 (-66.2; 86.6) 
CD4 201–350 128.7 (25.9) 142.2 (27.2)  13.5 (-8.2; 35.1) 15.5 (-18.4; 49.4) 34.1 (1.1; 67.1) 
CD4 > 350 169.9 (47.3) 226.1 (41.7)  56.2 (19.0; 93.5) 22.3 (-41.1; 85.7) 58.8 (3.3; 114.4) 
*Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” and dichotomous “holiday” indicator. 
**Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” dichotomous “holiday” indicator, and interaction of “study 
month” with the policy change indicator. 
ART = antiretroviral therapy; SD = standard deviation; CI = confidence interval
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Table 1.3: Interrupted time series effect estimates of August 2011 eligibility expansion on ART uptake among 
patients previously eligible, newly eligible, and not yet eligible.  
CD4 count at 
clinical 
diagnosis 
Mean monthly count of new 
ART initiators 
 Change in count of new initiators 
Apr 2010 – 
Aug 2011 
Mean (SD) 
Sept 2011 – 
June 2012 
Mean (SD)  
Crude change in 
mean 
(95% CI) 
Adjusted change in 
mean* 
(95% CI) 
Adjusted difference 
at the threshold** 
(95% CI) 
Overall 300.5 (61.9) 378.5 (74.2)  78.0 (23.4; 132.7) 95.5 (-1.3; 192.3) 117.6 (7.2; 228.0) 
CD4 ≤ 200 146.1 (30.8) 129.3 (28.0)  -16.8 (-41.2; 7.7) 10.6 (-28.6; 49.8) 16.0 (-30.1; 62.0) 
CD4 201–350 85.8 (19.1) 142.6 (26.8)  56.8 (38.6; 75.0) 73.0 (42.1; 103.9) 81.2 (46.6; 115.8) 
CD4 > 350 56.2 (18.9) 92.9 (24.9)  36.7 (19.2; 54.2) 30.3 (-6.9; 67.6) 28.9 (-14.1; 71.9) 
*Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” and dichotomous “holiday” indicator. 
**Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” dichotomous “holiday” indicator, and interaction of “study 
month” with the policy change indicator. 
ART = antiretroviral therapy; SD = standard deviation; CI = confidence interval 
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Table 1.4: Interrupted time series effect estimate of August 2011 eligibility expansion on ART initiation within six 
months among patients previously eligible, newly eligible, and not yet eligible.  
CD4 count at 
clinical 
diagnosis  
 
Percent initiating ART by six 
months 
  
Change in percent 
 
Apr 2010 – 
Aug 2011 
Mean (SD) 
Sept 2011 – 
June 2012 
Mean (SD) 
 
Crude change in 
percent 
(95% CI) 
Adjusted change in 
percent* 
(95% CI) 
Adjusted difference 
in percent at the 
threshold** 
(95% CI) 
Overall 32.4 (0.6) 34.4 (0.7)  1.9 (0.2; 3.7) -0.9 (-12.4; 10.7) 1.6 (-7.8; 10.9) 
CD4 ≤ 200 57.9 (1.0) 63.2 (1.2)  5.3 (2.2; 8.4) 4.0 (-2.7; 10.6) 4.6 (-2.3; 11.5) 
CD4 201–350 24.3 (1.2) 49.9 (1.3)  25.6 (22.2; 29.1) 5.5 (-8.8; 19.8) 10.8 (1.0; 20.6) 
CD4 > 350 2.9 (0.4) 4.3 (0.4)  1.4 (0.3; 2.6) -0.7 (-2.4; 1.0) -0.4 (-2.2; 1.3) 
*Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” and dichotomous “holiday” indicator. 
**Linear regression controlling for first-degree autocorrelation, with the following independent variables: a dichotomous policy 
change indicator (coefficient shown), continuous “study month,” dichotomous “holiday” indicator, and interaction of “study 
month” with the policy change indicator. 
ART = antiretroviral therapy; SD = standard deviation; CI = confidence interval 
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Table 1.5: Cox Proportional Hazards effect estimate of August 2011 eligibility expansion on time to ART initiation 
among patients previously eligible, newly eligible, and not yet eligible.  
CD4 count at clinical 
diagnosis 
Time to ART initiation 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
Adjusted HR at the 
threshold** 
(95% CI) 
Overall 1.18 (1.11; 1.26) 1.18 (1.06; 1.33) 1.08 (0.95; 1.22) 
CD4 ≤ 200 1.29 (1.20; 1.40) 1.06 (0.92; 1.23) 1.08 (0.92; 1.27) 
CD4 201–350 2.42 (2.16; 2.71) 1.47 (1.19; 1.82) 1.38 (1.11; 1.73) 
CD4 > 350 1.49 (1.11; 2.00) 1.19 (0.69; 2.06) 1.12 (0.63; 2.0) 
*Cox proportional hazards regression with the following independent variables: a dichotomous policy change indicator 
(coefficient shown), continuous “study month,” dichotomous “holiday” indicator, sex, and age. 
**Cox proportional hazards regression with the following independent variables: a dichotomous policy change indicator 
(coefficient shown), continuous “study month,” dichotomous “holiday” indicator, sex, age, and an interaction of “study month” 
with a dichotomous policy change indicator. 
ART = antiretroviral therapy; HR = hazard ratio; CI = confidence interval 
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Figure 1.1: Observed monthly count of new diagnoses over time at the Hlabisa HIV 
Treatment and Care Programme clinics in KwaZulu-Natal, South Africa, along with 
curve of predicted values and 95% confidence limits.*  
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*Predicted values based on the following model: 
Count = β0 + β1(study month)+ β2(guideline change)+ β3(holiday) 
Gray bar indicates month of policy implementation. 
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Figure 1.2: Observed monthly count of new ART initiators over time at the Hlabisa 
HIV Treatment and Care Programme clinics in KwaZulu-Natal, South Africa, along 
with curve of predicted values and 95% confidence limits.*  
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*Predicted values based on the following model:  
Count = β0 + β1(study month) + β2(guideline change) + β3(holiday) 
Gray bar indicates month of policy implementation. 
ART = antiretroviral therapy
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Figure 1.3: Observed monthly percent of new patients who initiate ART within six 
months of first visit at the Hlabisa HIV Treatment and Care Programme clinics in 
KwaZulu-Natal, South Africa, along with curve of predicted values.*  
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*Predicted values based on the following model:  
% who initiate by 6 months = β0 + β1(study month)+ β2(guideline change)+ β3(holiday) 
Gray segment indicates months excluded from regression model due to patients’ exposure to 
both sets of guidelines in first six months in HIV care. 
ART = antiretroviral therapy
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Figure 1.4: Kaplan-Meier failure curves of treatment initiation rates before (blue) 
and after (red) the guideline change, adjusted for holiday, sex, and age using 
inverse probability of treatment weighting. 
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ART = antiretroviral therapy
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STUDY 2 
Simplified treatment regimens and retention in HIV care: A regression 
discontinuity study in South Africa. 
 
Introduction 
While HIV has become a highly manageable infectious disease, it still 
requires lifelong, frequent interaction with the health care system for an infected 
individual. Even a patient who has achieved viral suppression typically must see 
a clinician every few months for monitoring and medication pickups and must 
adhere to medication on a daily basis. Patients with poor adherence to 
antiretroviral therapy (ART) or incomplete clinic attendance have been shown to 
be at increased risk of antiretroviral resistance [23,24], hospitalization [25,26], 
transmission [30], and mortality [27–29].  
One potentially important barrier to adherence and retention is regimen 
complexity, a continuous challenge for individuals taking lifelong therapy [33]. 
Early antiretroviral treatment regimens involved multiple pills taken multiple times 
per day. Fixed dose combination drugs (FDCs) of one single pill containing a full 
three-drug antiretroviral therapy (ART) regimen provide a potential solution to 
poor adherence, as they reduce the burden on the patient and are more 
convenient than taking multiple pills [39]. FDCs are now recommended by the 
World Health Organization (WHO) for antiretroviral therapy because of their 
potential to improve adherence and retention, as well as their lower cost and 
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easier supply, storage, and distribution [20].  
South Africa, the country with the largest HIV treatment program in the 
world with 3.4 million people on treatment at the end of 2015 [21], is estimated to 
have only 48.3% retention in care at 60 months [22]. In 2013, South Africa 
adopted the WHO recommendation to use FDCs for first-line ART into its 
national treatment guidelines [6]. FDCs have been gradually rolled out, first to all 
new treatment-eligible HIV patients initiating therapy, and subsequently for 
patients already established on first-line treatment. FDCs have been 
recommended for all patients newly initiating ART in the country’s public facilities 
since April 1, 2013 [85]. 
Clinical trials in North America, Europe, and Australia have shown 
improved adherence to single-pill compared to multiple-pill regimens among 
treatment-naïve patients [39–41], but few studies compare these regimens in 
non-trial settings. Moreover, we are not aware of any observational studies 
evaluating differences in retention or adherence for multiple-pill versus single-pill 
regimens in resource-limited settings. Understanding the impact of single-pill 
FDC regimens on observed retention and adherence has implications for patient-
level ART decisions as well as national treatment policies, both for HIV and for 
chronic diseases with potential for simplified treatment regimens. Using a quasi-
experimental regression discontinuity design, we evaluated the causal effect of 
initiating FDC treatment compared to multiple pills on clinical retention in a large 
public sector clinic in South Africa. 
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Methods 
Data and Study Population 
This study used data from the Themba Lethu Clinic cohort in South Africa, 
a large outpatient public sector HIV treatment clinic in Johannesburg, South 
Africa [86,87]. Since Themba Lethu began operating in 2004, the clinic has 
initiated over 40,000 patients on treatment. Patient details including demographic 
information, lab results, medications prescribed, visit history, clinical conditions, 
and follow-up status (i.e. in care, died, lost to follow-up, or transferred out) were 
captured in an electronic medical record called TherapyEdge-HIV™ at the time of 
the clinical encounter. Patients were typically seen for medical follow-up visits at 
months 1, 3, 6, and 12-monthly thereafter. Viral load was measured at 6 and 12 
months, and annually thereafter until 2013 when the 12-month measure was 
eliminated. ART pickups were monthly for the first 6–12 months on treatment and 
every 2 months thereafter once stable [86]. In October 2012, Themba Lethu clinic 
installed an automated system for dispensing ART to shortened waiting times for 
drug pickup. Mortality is determined through linkage with South Africa’s National 
Vital Registration System for patients who provided a national ID number upon 
registration at the clinic (71% of our study sample); for patients without an ID, 
clinic counselors attempt to determine the vital status of patients lost to follow-up 
through phone calls and home visits [47].  
Pharmacy dispensing data are recorded in a separate electronic system 
and were available from September 2012 through October 2014. Single-tablet 
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FDCs of tenofovir/emtricitabine/efavirenz have been recommended as first-line 
treatment since April 1, 2013 [85], replacing a prior regimen which included three 
pills, once per day, of tenofovir, lamivudine or emtricitabine, and efavirenz or 
nevirapine [81]. The April 2013 guideline change also extended ART eligibility to 
patients with WHO stage III disease [6]. No other major clinical policy shifts were 
implemented during the period of the study. 
In order to evaluate the impact of the policy change from multiple pills to 
FDCs on retention, we included treatment-naïve adults ages 16 and older who 
initiated standard first line HIV treatment (any of the combinations described 
above) between September 1, 2011 and August 31, 2014, providing us with at 
least one year of follow-up data for all patients. Throughout the study period, 
patients were eligible for ART with a CD4 count ≤350 cells/µL [5] or WHO Stage 
4 disease (regardless of CD4 count), with eligibility extended to patients with 
WHO Stage 3 disease in April 2013. We excluded pregnant women and patients 
co-infected with tuberculosis (whose retention outcomes are known to differ from 
those of the general population) [88–90], as well as 17 patients who became 
eligible due to WHO Stage 3 disease and 125 patients who initiated ART at a 
time when both FDCs and multiple pills were available (after September 1, 2012) 
but did not have record of initial treatment.  
Approval for this analysis was granted by the Human Research Ethics 
Committee of the University of the Witwatersrand and by the Institutional Review 
Board of Boston University. 
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Study design 
We performed a regression discontinuity analysis [11,91–93] to assess 
whether the introduction of FDCs as standard first-line therapy had an effect on 
attrition from care. This quasi-experimental study design avoids confounding by 
comparing outcomes among patients who initiated treatment immediately before 
versus immediately after the guideline change. Under the assumption that dates 
of ART initiation are as-good-as-randomly assigned around the policy change, 
the difference in outcomes at the threshold is interpretable as the intention-to-
treat effect of the single-pill FDC policy change.  
 
Exposure and outcome assessment 
Our primary measure of attrition was lapse in care within the first year on 
treatment, defined as any ≥3-month gap in care that was not explained by a 
documented transfer to another clinic. This includes deaths and losses to follow-
up for patients with final visits within the first 9 months on treatment (allowing for 
3 months’ absence before the end of the first year), and likely includes 
undocumented transfers to another clinic as well. We also examined: (1) 
disengagement from care within the first 12 months on ART (a subset of “lapse in 
care” including only patients who did not return to care within the study period), 
(2) failure to fulfill the recommended 6-month viral load testing (defined as no 
viral load lab result between 4 to 8 months following ART initiation), and (3) fewer 
than 2 ART pickups in the first year on treatment.  
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Our primary exposure was being prescribed an FDC versus multiple pills 
for initial first line HIV treatment (“regimen type”). Regimen type was not 
consistently documented in clinical notes (52% missing), and pharmacy records 
corresponding to the date of treatment initiation did not always exist (5% 
missing). We classified treatment as FDC if either source indicated an FDC 
regimen type. We assumed that patients who initiated ART prior to the 
September 2012 availability of pharmacy data were prescribed multiple pills, as 
FDCs were not yet available to the clinic at this time. We used policy-
recommended treatment (i.e., date of initiation after April 1, 2013) as the 
“randomization” variable for our regression discontinuity analysis. 
 
Statistical analysis 
Regression discontinuity analysis fits local linear regression curves to data 
on the probability of an outcome on either side of a “threshold” (here, the date of 
the policy change), and measures the vertical distance between these curves to 
obtain the risk difference at the threshold [11,62,92,93]. We fit these curves to 
the risk of attrition across dates of ART initiation, with the threshold set to April 1, 
2013, to measure the “intention to treat” (ITT) effect, or the effect of the policy 
change on the population-level risk of attrition. In order to estimate the effect of 
treatment, single-pill FDCs versus multiple-pill regimens, on the risk of attrition, 
we ran a two-stage least squares regression: 
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First stage: 
E[Ti|Zi] = β0 + β1(Zi – c) + β2 1[Zi < c] + β3(Zi – c)*1[Zi < c] 
Second stage: 
E[Yi|T̂i] = β0 + β1(Zi – c) + β2(T̂i) + β3(Zi – c)*(T̂i) 
where Ti represents treatment regimen, Zi represents an individual’s date of ART 
initiation, and c is a constant for April 1, 2013.  
For the first stage of this two-stage least squares regression we fit local 
linear regression curves before and after the April 2013 threshold to estimate the 
probability of FDC treatment for each individual. We used this result as a 
predictor in a second-stage local linear regression model to estimate the risk of 
attrition according to each individual’s probability of FDC treatment. The second-
stage coefficient for the predicted probability of FDC variable (β1) is the Complier 
Average Causal Effect (CACE) of FDC treatment on attrition, specific to an 
unidentifiable population of “compliers” who would have been prescribed 
multiple-pill treatments had they initiated ART before the policy change, or FDCs 
had they initiated ART after the policy change. In contrast, prescriptions for 
“never-takers” (of FDC) and “always-takers” are not are not expected to vary 
according to the policy recommendation. The CACE estimated by two-stage least 
squares is equal to the ITT effect divided by the change in probability of FDC 
treatment at the threshold (β1 from the first-stage local linear regression). 
While logistic regression can provide a better fit to dichotomous outcomes 
with high or low risks, two-stage least squares regression requires the use of 
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linear regression to provide an unbiased estimate. We therefore used linear 
regression models but performed a sensitivity analysis with logistic regression. 
To fit local linear regression curves that were not influenced by patterns in 
attrition long before or after the policy change, we limited our analyses to patients 
whose ART initiation fell within a subset of dates around the time of the policy 
change. We selected different subsets for each analysis using a data-driven 
optimal bandwidth estimation process that balances the fit of the linear curve 
versus precision of the estimated outcome at the threshold (a smaller bandwidth 
provides a better linear fit, while a larger patient subset allows for greater analytic 
certainty) [94,95]. We calculated 95% confidence intervals by bootstrapping with 
1000 replicates. 
Three conditions are necessary to be able to identify the causal effect of 
FDC treatment on attrition using regression discontinuity design: (1) the date of 
implementation of the new guidelines must be known; (2) frequency of ART 
initiation must be smooth around the time of the policy change to illustrate that 
initiation dates were not manipulated to intentionally place patients in either 
exposure category (i.e., exposure is “randomized”); and (3) there must be no 
other reason to find a shift in the risk of attrition at the date of the guideline 
change. 
We tested the first condition by plotting regimen type over time to observe 
that the new guidelines were actually implemented on April 1, 2013. We then 
evaluated exposure randomization by performing the McCrary sorting test [96], 
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which tests for bunching of ART initiation around the date of the policy change. 
While the third condition is untestable, we evaluated its plausibility using local 
linear regression to test for discontinuity in patient baseline characteristics at the 
policy threshold. Failure to find evidence of any other change at the time of the 
implementation of the new guidelines would support our assumption that any 
difference in outcomes resulted from the policy change. 
We also evaluated the potential for selection bias arising from the use of 
pharmacy data for classification of regimen type. Because drug pickup is 
associated with retention in care (our outcome) [97], an association between 
completeness of dispensing records and regimen type (our exposure) would 
induce selection bias. We compared exposure proportions over time for the two 
data sources to assess the potential for selection bias. 
 
Results 
Cohort characteristics 
Around the time of the policy change (±180 days), the population of 
patients initiating treatment at Themba Lethu was 43% male with a mean age of 
38.5 (±9.9) and mean CD4 at baseline of 193.9 (±164.1). 45% of patients were 
anemic and 14% presented with WHO stage 3 or 4 HIV (Table 2.1). Linear 
regression of these characteristics over time, allowing for change in intercept at 
April 1, 2013, showed a small decrease in age at ART initiation (-2.5 years; 95% 
CI: -4.5; 0.0) and a possible decrease in CD4 count (-18.1 cells/µL; 95% CI:         
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-60.2; 24.0) at the date of the policy change. Prescription of FDC increased by 
70.8% (95% CI: 62.9; 78.7) (Figure 2.1, Appendix 1) after the policy change. All 
other covariates remained constant at this threshold (Table 2.1, Appendix 2). 
Of 1287 patients initiating a single-treatment FDC regimen between 
September 2011 and September 2014, 98.6% were prescribed 
tenofovir/emtricitabine/efavirenz. Of the 3214 patients prescribed multiple-pill 
regimens, treatments included tenofovir/lamivudine/efavirenz (79.1%), 
stavudine/lamivudine/efavirenz (12.5%), tenofovir/ lamivudine/nevirapine (4.6%), 
tenofovir/emtricitabine/efavirenz (2.8%), and stavudine/lamivudine/nevirapine 
(1.0%). A comparison of monthly treatment type distribution (FDC versus multiple 
pills) from clinic records versus pharmacy data showed similar distributions over 
time from the two data sources (Appendix 3), suggesting that completeness of 
pharmacy records did not differ by regimen type. 
 
Initiation of patients on a single-tablet FDC regimen 
We observed a clear shift in prescribed treatment from multiple-pill to 
single-pill ART at the threshold of April 1, 2013 (Figure 2.1, Appendix 1). FDC 
was prescribed to 2.5% and 85.7% of new patients in the six months before and 
after the policy change, respectively (Table 2.1). The McCrary density test found 
no evidence of bunching of frequency of ART initiation around April 1, 2013 
(Appendix 4), supporting the assumption that regimen was effectively 
randomized at the threshold. We also found only slight discontinuities in 
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measured baseline covariates at the time of the guideline change (Table 2.1, 
Appendix 2), reinforcing our assumption that a change in attrition at that time 
point must be attributable to the new policy. 
 
Retention on HIV treatment 
Intention-to-treat (ITT) regression discontinuity results, describing 
population-level changes in outcomes at the time of the policy change, are 
presented in Table 2.2. Our primary outcome, the number of patients 
experiencing a ≥3-month lapse in care, dropped from 22% to 11% (-11 
percentage points; 95% CI: -22; -1) within the 128-day bandwidth before and 
after the policy change. One-year disengagement from care decreased from 
27.9% to 17.0% (-10.9 percentage points; 95% CI: -23; 1.5), noncompliance with 
viral load monitoring decreased from 37.6% to 28.3% (-9.3 percentage points; 
95% CI: -21; 2), and the proportion of patients with <2 pharmacy pickups in the 
first year decreased from 9.3% to 3.5% (-5.8 percentage points; 95% CI: -11.5;    
-0.2). Plots of our main outcome (Figure 2.2), secondary outcomes (Figure 2.3), 
and monthly retention in care (Figure 2.4) illustrate the changes in attrition at the 
policy threshold.  
In our exploration of logistical changes related to treatment at the time of 
the policy change, we observed no notable change in the number of pharmacy 
pickups among patients remaining in care (Appendix 5), implying that the 
quantity of daily doses dispensed at one pickup was the same for multiple-pill 
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and FDC regimens. 
Because not all patients were prescribed FDC after the policy change, the 
ITT underestimates the causal effect of FDC on retention in care. However, we 
can obtain the complier average causal effect (CACE) by weighting the ITT by 
the probability of being prescribed FDC. Using local linear regression to control 
for time trends, we found a 66-percentage point increase in FDC prescription 
after the guideline change (95% CI: 57; 75) within the ±132-day bandwidth before 
and after April 1, 2013 (Appendix 6). A sensitivity analysis using logistic 
regression provided similar estimates (Appendix 7). We then estimated the 
CACE by controlling for the probability of FDC treatment for each outcome, 
revealing an 18-percentage point decrease in 3-month lapse in care (95% CI -33; 
3), a 16-percentage point decrease in one-year disengagement from care (95% 
CI -34; -3), a 14-percentage point decrease in missed viral load measures (95% 
CI -30; 1), and a 6-percentage point decrease in patients with <2 pharmacy 
pickups in the first year (-95% CI -13; 1) (Table 2.2).  
 
Discussion 
We set out to address whether simplified regimens improve HIV treatment 
outcomes in a setting that controlled for confounding. Exploiting the rapid 
implementation of a policy to start HIV patients on single-tablet ART — replacing 
a more complex multiple-pill regimen — we assessed the causal impact of this 
simplified regimen on retention in care using a regression discontinuity design. 
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We found that attrition in our study population dropped by 11 percentage points, 
from 22% to 11%, following the introduction of a single-tablet FDC regimen, a 
relative decrease of 50%. Among “compliers,” whose regimen type was 
determined by the policy change, the reduction in attrition was 18 percentage 
points.  
Three meta-analyses [39–41] and several observational studies [43–
46,98–101] have compared adherence to single-tablet versus multiple-tablet 
regimens, with most studies reporting higher adherence for single-tablet 
regimens. However, these studies were all conducted in North America and 
Western Europe, and their findings might not be generalizable to settings in sub-
Saharan Africa. Additionally, all of these studies excluded patients who were lost 
to follow-up rather than evaluating retention as an outcome. This is the first study 
to evaluate clinic retention in HIV care associated with single-pill versus multiple-
pill ART in sub-Saharan Africa.  
Increased adherence [39,40], greater patient satisfaction [102], and 
improved quality of life [103] are all documented benefits of FDCs that might 
have contributed to our findings of decreased attrition. We found this 
improvement despite a lack of change in frequency of required pharmacy 
pickups. Given the simplicity of storage and distribution for FDCs relative to 
multiple-pill treatments, we suspect that more widespread distribution to local 
pharmacies in the future could lead to an even greater reduction in attrition.  
The most commonly prescribed FDC at the time of the policy change in 
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South Africa, tenofovir/emtricitabine/efavirenz, and the leading multi-pill regimen 
at the time, tenofovir/lamivudine/efavirenz, have similar risks of toxicity [104,105]. 
Thus it is likely that our observed reduction in attrition was related to the lower pill 
burden rather than any increased tolerance to treatment. 
Our findings can provide important insight for South Africa as it strives to 
achieve sustained treatment for 90% of individuals who have tested HIV-positive 
by 2020 according to the UNAIDS target [106]. A cost-benefit analysis of 
interventions targeting improved retention should consider FDCs against other 
interventions: case managers, adherence clubs, reminder SMS messages and 
phone calls, posters, and brochures. Given the simplicity of supplying FDCs 
relative to implementing these other strategies, as FDCs replace an existing 
treatment rather than incurring an additional cost, it might be worthwhile for the 
South African government to increase its investment in development, supply, and 
distribution of FDCs. 
Our study had several limitations. In defining our outcome, the lack of 
reliable mortality data required us to use a composite of mortality plus loss to 
follow-up rather than evaluating the two separately. Regarding exposure 
classification, our use of pharmacy data could potentially have induced selection 
bias if completeness of dispensing records were associated with regimen type 
[97]. However, our findings of similar prescription patterns between clinic notes 
and pharmacy data suggest that this is unlikely to contribute substantial bias. 
Additionally, while we are unaware of other policy changes at the time of FDC 
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introduction, our results might nonetheless be inflated if the introduction of the 
new treatment led to an overall focus on improving patient care. This could 
explain the large drop in attrition followed by a gradual return to pre-FDC levels. 
Another limitation is that our regression discontinuity CACE results only apply to 
an unidentifiable cohort of individuals whose regimen was determined by the 
policy at the time (“compliers”). However, compliers represent a large portion of 
the population at the time of the policy change (Appendix 6) and the results are 
similar to the intention to treat analysis.  
 
Conclusion 
This was the first analysis comparing clinic retention on single-tablet FDCs 
versus multiple-pill ART in a low-resource setting. We found that the switch to 
FDCs as the recommended first-line treatment for HIV led to a large reduction in 
clinic attrition in this large public-sector cohort. Simplified treatment regimens 
may offer substantial value to the real-world management of HIV, and also 
chronic diseases, in low-resource settings. 
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Table 2.1. Baseline characteristics of patients initiating antiretroviral therapy at 
Themba Lethu Clinic in Johannesburg, South Africa 180 days before and after the 
policy change to recommend use of fixed dose combination regimens. 
 Total 
 
n = 1124 
180 days 
before policy 
change 
 
n = 599 
180 days 
after policy 
change 
 
n = 525 
Discontinuity at 
policy change*                      
Risk Difference 
(95% CI) 
Male   
(n, %) 
487 (43.3%) 252 (42.1%) 235 (44.8%) -0.3% (-12.0; 11.4) 
Age at initiation  
(mean, SD) 
38.5 (9.9) 38.6 (9.5) 38.5 (10.3) -2.2 (-4.5; 0.0) 
CD4 at baseline   
(mean, SD) 
193.9 (164.1) 196.7 (163.3) 190.9 (165.2) -18.1 (-60.2; 24.0) 
Anemia at baseline  
(n, %) 
502 (44.7%) 271 (45.2%) 231 (44.0%) 3.5% (-8.2; 15.1) 
WHO Stage ≥3   
(n, %) 
158 (14.1%) 82 (13.7%) 76 (14.5%) 4.8% (-3.7; 13.3) 
Assignment to 
FDC regimen (n, %) 
465 (41.4%) 15 (2.5%) 450 (85.7%) 70.8% (62.9; 78.7) 
*Calculated using linear regression on data within ±180 days of the policy change, with 
separate slopes before and after the policy change. The discontinuity represents the 
change in intercept at the policy change.  
CI = confidence interval; SD = standard deviation; WHO = World Health Organization; 
FDC = fixed-dose combination 
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Table 2.2. Regression discontinuity results for attrition outcomes associated with the April 1, 2013 switch to fixed-
dose combination treatment as standard first-line ART at Themba Lethu Clinic in Johannesburg, South Africa. 
 Intention-to-Treat  Complier Average Causal Effect 
Outcome Bandwidth* 
Predicted percent 
immediately before  
April 1, 2013 
(95% CI) 
Predicted percent 
immediately after  
April 1, 2013 
(95% CI) 
Risk Difference 
(95%CI) 
 Bandwidth* 
Risk Difference 
(95%CI) 
≥3-month lapse 
in care 
±128.4 21.8% (15.9; 27.7) 10.5% (5.1; 16.0) -11.3 (-22.0; -0.6)  ±131.9 -18.0 (-33.6; -2.4) 
Disengagement 
from care in first 
year 
±115.3 27.9% (20.7; 35.1) 17.0% (10.5; 23.5) -10.9 (-23.3; 1.5)  ±120.5 -15.7 (-34.3; -2.9) 
No 6-month viral 
load monitoring 
±162.6 37.6% (29.4; 45.7) 28.3% (20.3; 36.3) -9.3 (-20.7; 2.0)  ±177.3 -14.2 (-29.8; 1.4) 
Insufficient ART 
pickup 
±181.1 9.3% (5.4; 13.1) 3.5% (-0.3; 7.2) -5.8 (-11.5; -0.2)  ±219.6 -6.1 (-12.9; 0.8) 
* Optimal bandwidth using Imbens-Kalyanaraman method [94] as implemented by Calonico, Cattaneo, and Titiunik [95]. 
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Figure 2.1. Monthly percent of all patients initiating standard first-line ART at 
Themba Lethu clinic in South Africa who were prescribed a single-pill regimen. 
 
Dots represent monthly percentages; line represents smooth local linear regression with 
a 100-day bandwidth. 
ART = antiretroviral therapy 
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Figure 2.2. Three-month lapse in care among patients starting antiretroviral 
therapy before and after the switch to a single pill regimen at Themba Lethu Clinic 
in Johannesburg, South Africa. 
 
 
Dots represent monthly percentages; line represents smooth local linear regression with 
the optimized CACE bandwidth of 132 days. 
ART = Antiretroviral therapy   
53 
 
 
Figure 2.3. Secondary attrition outcomes among patients who initiated 
antiretroviral therapy at Themba Lethu Clinic in Johannesburg, South Africa: (A) 
Disengagement from care within one year; (B) Failure to have 6-month viral load 
measurement; (C) Only 1 ART pickup in first six months on treatment. 
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 ART = Antiretroviral therapy 
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Figure 2.4. Results of 12 local linear regression intention-to-treat models of the 
effect of the April 2013 recommendation to use FDC treatment for first-line ART on 
retention in care by each month of the first year on treatment. Top: Estimated 
percent remaining in care immediately before and immediately after new treatment 
recommendation; Bottom: Risk difference of percent remaining in care 
immediately after versus immediately before the new policy.  
 
Model: Pr(In care at X months) = β0 + β1(post-April 2013 indicator) + β2(date of treatment 
initiation – April 1, 2013) + β3(post-April 2013 indicator)* (date of treatment initiation – 
April 1, 2013) 
Top plot: “Pre” = β0; “Post” = β0 + β1 
Bottom plot: β1 ± 1.96 * SE(β1) 
RD = risk difference; ART = antiretroviral therapy; FDC = fixed-dose combination
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STUDY 3 
Who benefits most from the introduction of single-pill antiretroviral 
therapy? 
Introduction 
In September 2016, South Africa, the country with the largest HIV-infected 
population [3] and an HIV treatment program far larger than any other in the 
world [21], extended public-sector access to antiretroviral therapy (ART) to all 
HIV-infected individuals [8]. Previously, adult ART eligibility was based largely 
CD4 count (immunosuppression levels) with other allowances for those with high 
WHO clinical stage, tuberculosis or pregnancy [7].The introduction of a universal 
“test and treat” strategy of ART for all regardless of CD4 count not only increased 
the size of the patient population, but is also expected to bring in a healthier 
patient population.  
The ultimate goal of HIV treatment programs is for patients to achieve viral 
suppression, both for the wellbeing of individual patients and for the public health 
target of minimizing secondary transmission. Increased linkage to care through 
universal test-and-treat will only improve levels of viral suppression if patients are 
retained in care. Strategies to improve retention in HIV care in South Africa have 
ranged from simple phone call and SMS reminders [107,108] to adherence clubs 
[107,109,110], peer health system navigators [107,108,111], and entire 
community mobilization [112]. We also recently found that the introduction of 
single-pill fixed-dose combination (FDC) pills for first-line ART in April 2013, 
57 
 
 
replacing several once-daily, multiple-pill regimens, led to increased retention in 
a large public HIV clinic in Johannesburg.  
Regimen simplification in the form of fewer doses per day or fewer pills 
per dose can prevent or relieve treatment fatigue, and has been used to improve 
treatment adherence for both infectious [33–35] and chronic [36–38] diseases. 
Most clinical trials comparing once-daily single-pill and multiple-pill HIV 
treatments found improved adherence to single-pill treatment [42–44] but some 
did not [45,46]. Population differences that might have led to these mixed results 
have not been examined. These studies also have limited applicability to the 
setting of South Africa, as none of the trials were performed in resource-limited 
settings. 
We used data from a large public-sector HIV clinic in Johannesburg to 
assess the potential for FDCs to improve clinic retention in South Africa’s rapidly 
shifting patient population. We employed a stratified instrumental variable 
analysis to evaluate the impact of single-pill FDC on clinic retention among 
patient sub-populations, and also standardized our analysis to the cohort of 
patients who entered care after the September 2016 implementation of universal 
test-and-treat. 
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Methods 
Data and Study Population 
We conducted this study using data from the Themba Lethu Clinic cohort 
in Johannesburg, one of the largest sites for government-funded HIV treatment 
and care in South Africa [86,87]. We included treatment-naïve adults ages 16 
and older who initiated standard first line HIV treatment within 180 days before 
and after April 1, 2013. We also standardized our effect estimates to the 
population of patients initiating ART at Themba Lethu clinic after the 
implementation of universal test-and-treat using covariate values for patients who 
initiated ART between September 1, 2016 and July 31, 2017.  
We excluded pregnant women and patients co-infected with tuberculosis 
(whose retention outcomes are known to differ from that of the general 
population), as well as 74 patients who did not have record of initial treatment 
and 3 patients who became eligible for ART as FDCs were introduced in April 
2013.  
Themba Lethu uses the TherapyEdge-HIV™ electronic medical record 
system for record-keeping, recording data on patient demographics, scheduled 
visits, lab results, medications, health conditions, and follow-up status. A 
separate electronic system for pharmacy records was introduced in September 
2012. 
The flow of clinical care at Themba Lethu follows national guidelines. 
During the study period, patients were eligible for ART with CD4 levels ≤ 350, 
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WHO clinical stage 3 (as of April 2013) or 4 disease, and if pregnant or co-
infected with tuberculosis, regardless of CD4 count. At the time of HIV diagnosis, 
a patient’s blood was drawn for CD4 testing and TB screening was performed. At 
the next visit, patients learned whether their CD4 and TB results qualified them 
for ART. The following visits included individual and group adherence counseling 
and additional ART workup blood tests (hemoglobin, liver function test, renal 
function test, creatinine clearance), and after a median of 21 days, the first round 
of ART was dispensed [113]. For the beginning of our study period, standard 
first-line ART included three pills, once per day, of tenofovir or stavudine, 
lamivudine or emtricitabine, and efavirenz or nevirapine [81]. Starting on April 1, 
2013, FDCs of tenofovir/emtricitabine/efavirenz were recommended as first-line 
treatment [85]. 
Following ART initiation, patients were typically seen for medical follow-up 
visits at months 1, 3, 6, and annually thereafter, with ARV pickups every 1–2 
months [86]. Mortality was determined through linkage with South Africa’s 
National Vital Registration System for patients who provided a national ID 
number upon registration at the clinic (71% of our study sample); for patients 
without an ID, clinic counselors tracked patients with missed appointments 
through phone calls and home visits [47]. 
This study was approved by the Human Research Ethics Committee of 
the University of the Witwatersrand and by the Institutional Review Board of 
Boston University. 
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Study design 
We performed instrumental variable (IV) analyses adjusted for patient 
characteristics, both overall and stratified by patient characteristic subgroup, to 
identify the causal effect of FDCs on attrition from care. We compared our overall 
IV result with a conventional “as-treated” ordinary least squares analysis that 
ignores the influence of the policy recommendation on prescribing practices. 
Finally, we standardized our IV effect estimate to the characteristics of the clinic 
population that initiated ART after implementation of universal test-and-treat in 
order to quantify the impact of FDCs on attrition in a changing patient population.  
 
Exposure, outcome, and modifiers 
Our outcome of interest was attrition, defined as a ≥3-month lapse in care 
within the first year on treatment that was not explained by transfer to another 
clinic. This includes deaths and losses to follow-up within the first year. Our 
primary exposure was initial “regimen type” of either single-pill FDC or multiple-
pill first-line ART. We reviewed regimen data both from the pharmacy records 
and clinic records; if FDC was recorded as a patient’s initial regimen in either 
data source, that patient would fall into the FDC regimen category. Our 
instrument for instrumental variable analysis was policy-recommended treatment 
(i.e., date of initiation after April 1, 2013). 
We examined additive effect modification of regimen type on attrition by 
several baseline patient characteristics, including sex, age at ART initiation, CD4 
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count, WHO clinical stage (lower stage represents less severe disease), and 
anemia status (defined as hemoglobin <13 g/dL for men and <11.5 g/dL for 
women). We also evaluated interactions of CD4 count with sex, stage, and 
anemia status, as well as interactions of anemia with sex and stage, in modifying 
the effect of FDC treatment on attrition. Measurements taken from three months 
before to one week after ART initiation were classified as baseline values. 
Baseline CD4 count was missing for 101 patients. We classified these patients 
into a separate “missing” CD4 category for our stratified analyses, and tested 
“best case” and “worst case” replacement for models adjusted by CD4 count.  
 
Statistical analysis 
We performed instrumental variable (IV) analysis [114,115], where the 
treatment was prescription to FDC versus multiple pills (“regimen type”), the 
outcome was one-year attrition from the clinic, and the instrument was an 
indicator for whether a patient initiated ART before or after the April 1, 2013 
policy change. We stratified our analysis by categories of sex, age, baseline CD4 
count, WHO clinical stage, and anemia status to evaluate additive effect 
heterogeneity across strata of the patient population. 
We used two-stage least squares linear regression, described below, to 
calculate the IV Complier Average Causal Effect (CACE), or the effect of FDC 
versus multiple pills among an unidentifiable subset of patients who would have 
been treated with multiple pills had they initiated ART before the policy change or 
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with FDCs had they initiated afterward. We 
First stage: 
E[Ti|Zi] = β0 + β1(Zi – c) + β2 1[Zi < c] + β3(Xi) 
 Second stage: 
E[Yi|T̂i] = β0 + β1(Zi – c) + β2(T̂i) + β3(Xi) 
 In the equations above, Ti represents treatment regimen, Zi represents an 
individual’s date of ART initiation, c is a constant for April 1, 2013, Xi is a vector 
of individual characteristics (sex, age, CD4 count, WHO stage, anemia), and Yi 
represents attrition. 
While comparison of treatment outcomes in the observational setting is 
often susceptible to confounding by indication, our IV analysis would avoid 
confounding if the instrument: (i) was strongly associated with treatment; (ii) had 
no direct effect on outcomes except through the treatment; and (iii) was 
“randomly assigned,” sharing no common causes with the outcome 
[114,116,117]. CACE analysis requires one additional assumption of no “defiers,” 
or patients who would always be prescribed the non-recommended treatment 
relevant to the time period in which they initiated treatment.  
We evaluated assumption 1 by running a linear regression to assess the 
correlation between our instrument, the policy-recommended treatment, and 
prescribed regimen type. While logistic regression often provides a better fit for a 
dichotomous outcome, only linear regression is guaranteed to produce 
unconfounded two-stage least squares effect estimates [115]. However, we 
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confirmed the robustness of this result using logistic regression. 
The remaining three assumptions cannot be empirically verified, but we 
feel that they are justifiable. To strengthen assumption 2, we restricted our 
analyses to 180 days before and after the guideline change, a time period during 
which we are quite certain that there were no other major changes to clinic 
practices. However, we should note that our effect estimates could be inflated if 
the change in treatment protocol inadvertently led to an increased focus on 
patient retention. We evaluated “random assignment” for assumption 3 by 
comparing the distribution of measured covariates between the pre- and post-
guideline change ART initiators. In addition, recognizing that unidentified secular 
trends in the characteristics of the clinic population over time could violate 
assumption 3 of “random assignment,” we added a linear time variable to our IV 
models. Finally, we find it likely that there were no defiers of the treatment 
recommendations (assumption 4), given the completeness of transition from 
multiple-pill to single-pill regimens. 
For comparison against our IV effect estimates, we ran a conventional as-
treated ordinary least squares regression analysis of the effect of FDC on 
attrition, with prescription to multiple pills versus FDC as the exposure and 
attrition as the outcome, controlling for time trends but ignoring the policy for 
treatment recommendations.  
We also generalized our overall CACE estimate to the population initiating 
care under universal test-and-treat by rerunning our IV analysis on the original 
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study population standardized to covariate distribution of patients initiating ART 
between September 2016 and July 2017. We used inverse probability weighting 
to generate standardization weights. 
We manually coded all two-stage least squares regression analyses in 
SAS, with bootstrapping to estimate robust 95% confidence intervals.  
 
Results 
During the study period from October 3, 2012 through September 28, 
2013 (April 1, 2013 ± 180 days), the study population was largely female 
(56.7%), with a median age of 37.5 (IQR: 31.1 – 44.9) and median CD4 at 
baseline of 164.0 (IQR 64.0 – 280.0). 45% of patients were anemic and 14% 
presented with WHO stage 3 or 4 HIV (Table 3.1). Patients initiating ART after 
the implementation of universal test-and-treat were more likely to have CD4 
counts > 350 cells/µL or missing baseline CD4 (Appendix 8), but were otherwise 
similar to the study sample. 
Patients missing baseline CD4 values were more likely to be male (53% 
versus 42%) and anemic (55% versus 44%). They were less likely to be 
prescribed FDCs (24% versus 43%) and more likely to have an attrition outcome 
(26% versus 14%) (Appendix 9). We included these patients in our analyses but 
classified them as a separate CD4 category. 
We did not observe any discontinuities in patient characteristics at the 
time of the guideline change (Appendix 2), supporting the assumption for 
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instrumental variable analysis that initiation of ART before versus after the policy 
change was “random,” or unrelated to patients’ risk of attrition.  
Within our study period, 465 patients (41%) were prescribed single-pill 
FDC treatment and 659 (59%) were prescribed multiple-pill regimens (Table 3.1). 
Patients prescribed FDCs had slightly higher CD4 levels at baseline and were 
less likely to be anemic (Table 3.1). Before FDCs were recommended, 2.5% of 
patients were nonetheless prescribed this single-pill treatment; afterward, 85.7% 
were prescribed FDCs (Figure 3.1, Appendix 10). This large shift supports the 
assumption of the instrument being a strong predictor of the exposure.  
Overall, the one-year attrition percent was similar for patients on FDCs 
and multiple pills (13.8% and 15.9%, respectively) (Table 3.1). Thus, our 
adjusted as-treated ordinary least squares regression found little difference in 
attrition for patients on FDCs versus multiple pills (Table 3.2). However, our 
adjusted instrumental variable (IV) analysis of the Complier Average Causal 
Effect (CACE) estimated that treatment with FDCs led to a 17 percentage point 
decrease in attrition (95% CI: -29; -5) compared to treatment with multiple-pill 
regimens, aligning more closely with visualized trends (Figure 3.1). A sensitivity 
analysis of this association using logistic regression produced similar results 
(Appendix 11).  
After observing differences between patient subpopulations regarding 
changes in retention in care, we stratified our analyses to understand what 
modified the overall effect estimate. Adjusted IV CACE risk differences of attrition 
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are reported in Table 3.3; observed pre-guideline change (“pre”) and post-
guideline change (“post”) values are reported in Appendix 12. Appendix 13 
summarizes stratified results from ordinary least squares and regression 
discontinuity models. 
Observed attrition in men decreased from 20.8% in the “pre” period to 
17.2% in the “post” period, while attrition among women started lower, at 15.8%, 
and decreased to 11.6%. On adjusted analysis, FDCs led to a greater drop in 
attrition for women (CACE risk difference -0.25 (-0.42; -0.09)) than for men 
(CACE risk difference -0.08 (95% CI: -0.26; 0.11)). 
Among patients with anemia at baseline, observed attrition decreased 
from 23.2% in the pre period to 18.7% in the post period, compared to 
nonanemic patients whose attrition levels decreased from 12.6% to 10.1% from 
pre to post. However, on adjusted analysis controlling for time, covariates, and 
compliance levels, patients without anemia saw a greater effect of FDCs on 
attrition compared to those with anemia (CACE risk difference -0.24 (95% CI:      
-0.41; -0.08) and -0.11 (95% CI: -0.31; 0.09), respectively).  
Other indicators of disease severity, WHO clinical stage and CD4 count, 
also modified the effect of FDCs on attrition. While observed changes in attrition 
were similar for patients of low (1 or 2) versus high (3 or 4) clinical stage, 
decreasing from 16.7% to 13.0% among low-stage patients and from 24.1% to 
20.7% among high-stage patients, adjusted CACE estimates showed a greater 
reduction in attrition from FDCs among patients with lower stage disease (CACE 
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risk difference -0.20 (95% CI: -0.32; -0.07) compared to -0.07 (95% CI: -0.45; 
0.32) for high stage). Stratified by CD4 count, we found the highest observed 
attrition in the “pre” period among the sickest patients with CD4 ≤ 100 cells/µL 
(23.4%) and the lowest attrition among patients with CD4 201 – 350 cells/µL 
(9.8%), but the greatest observed decrease in attrition among the least sick 
patients with CD4 > 350 cells/µL (16.4% to 9.8%). However, consistent with 
results stratified by clinical stage, adjusted CACE revealed a monotonic 
relationship between CD4 and FDC-related changes in attrition, with the greatest 
decrease among the least sick patients (CACE risk difference -0.58, 95% CI:       
-1.58; 0.42) and no change among the sickest patients (CACE risk difference 
0.00; 95% CI: -0.25; 0.26). Separate models testing interactions of CD4 with sex, 
stage, and anemia status, and interactions of anemia with sex and stage, 
showed no meaningful effect modification between covariates. 
Results were consistent across instrument-adjusted models (IV, 
regression discontinuity) (Table 3.2), and were robust to replacement of missing 
CD4 measures with high or low values. IV regression standardized to the 
population initiating care under universal test-and-treat produced a slightly larger 
effect estimate (CACE risk difference -0.20; 95% CI: -0.33; -0.06) (Table 3.2).  
 
Discussion 
We previously found that treatment with single-tablet FDCs compared to 
multiple-pill regimens led to improved patient retention in HIV care, and here we 
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aimed to identify which subsets of the patient population were most (and least) 
affected. We found that this effect was strongest among patients who were 
women, non-anemic, had high CD4 counts, and had low WHO stage disease, 
suggesting that, in general, FDCs led to a greater improvement in retention 
among healthier patients.  
Universal ART eligibility in South Africa will bring an increasingly healthy 
patient population into HIV care. We already found a shift toward healthier ART 
initiators in this clinic population in the year following the introduction of universal 
test-and-treat, and we are expecting an even greater shift as outreach programs, 
such as mobile HIV screening [118] and fast-tracked treatment initiation [107], 
aim to engage a broader patient population. Interventions to promote continuity 
of care among healthier patients are therefore becoming increasingly critical. 
FDCs provide a relatively cheap and simple means of improving retention in care 
in this new patient population.  
We suspect that FDCs improve retention in care by preventing the onset 
of treatment fatigue, defined as decreased motivation to maintain vigilance in 
adhering to a long-term treatment regimen [31]. Little is known about the impact 
of treatment fatigue on HIV treatment adherence and retention, and about 
differential susceptibility to treatment fatigue in general [31]. However, it is likely 
that this phenomenon disproportionately affects healthier patients who are not 
experiencing symptoms of HIV and therefore see treatment as an option rather 
than a necessity. Studies throughout sub-Saharan Africa have found lower levels 
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of adherence to treatment among healthier patients [119–122], supporting this 
theory. While healthier patients in our cohort actually had higher baseline levels 
of clinic retention, this is likely due to the fact that our definition of attrition 
includes mortality, which is lower among healthier patients.  
Our finding that FDCs did not improve rates of retention in HIV care 
among men is disappointing, as it is well known that men have particularly high 
rates of attrition [48,123,124]. Several qualitative studies examining men’s lack of 
participation in HIV care have identified a complex series of barriers, including 
stigma and discrimination from family and friends, distrust that health care 
providers would maintain confidentiality, personal or familial alcohol use, and 
denial due to an overarching sentiment that illness from HIV-infection threatens a 
man’s masculine representation [124–127]. Unfortunately, it seems unlikely that 
simply providing FDCs would resolve these issues without additional targeted 
social interventions. 
We focus on instrumental variable CACE estimates, describing the causal 
effect of FDCs on “compliers,” despite their inconsistency with our “as-treated” 
conventional analysis, describing the observed outcomes of FDC treatment 
among all patients. A number of factors likely contribute to this discrepancy. First, 
our IV analysis eliminates confounding by indication, a common bias in 
conventional comparative treatment analyses, where treatment decisions are tied 
to the patient’s risk of the outcome [128]. We suspect that patients deemed likely 
to be lost to follow-up might have been more likely to be prescribed FDCs both 
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before and after the policy change, as a simpler, less burdensome treatment 
regimen.  We cannot know for certain how compliers differ from never-takers and 
always-takers, but it is these unmeasured differences that underlie the large 
discrepancy in causal and non-causal outcomes.   
Our study had several limitations. First, we expect some amount of 
information bias in classifying our exposure, outcome, and covariates. We used 
both pharmacy and clinic records to assess regimen type, and while these two 
sources show similar patterns, it is possible that some clinic records misreported 
the true treatment received. With respect to our outcome of attrition, a 
combination of mortality and loss to follow-up, it is likely that some patients with 
an attrition outcome were actually unreported transfers to another clinic. These 
patients might be more similar to those remaining in care than to those lost to 
follow-up. Finally, CD4 count, used for stratified and adjusted models, is subject 
to measurement error.  
Although we focus on differences in outcomes between strata of patients, 
we do recognize that even the largest gaps between strata have overlapping 
confidence intervals. However, we believe that the observed differences are 
noteworthy, and that the lack of significance is likely due to small sample sizes, 
given the consistent pattern of stronger effects in healthier patient subsets. 
Additionally, while instrumental variable methods have clear advantages, they 
cannot provide us with effect estimates for never-takers and always-takers of 
FDC treatment. We expect that these patients differ from compliers in systematic 
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ways, explaining the bias behind the null effect estimate from our simple linear 
as-treated regression, but we would require additional contextual background 
from physicians and patients to explain these differences. Finally, we recognize 
the potential for bias in our effect estimates if the introduction of FDCs led to 
undocumented changes in clinic practices, which would have augmented the 
apparent impact of FDCs on attrition.  
 
Conclusion 
This quasi-experimental analysis revealed that the introduction of a single-
tablet FDC regimen reduced attrition from care in this large public-sector HIV 
treatment clinic. We observed the largest reductions among the healthiest 
patients. Now that South Africa has rolled out universal treatment for all HIV-
infected individuals, and patients are engaging in care at earlier stages of 
disease, we expect that the availability of FDCs will play a large role in improving 
the patient experience and increasing patient retention in care. However, we 
continue to observe high levels of attrition among men and patients who initiate 
care with more severe illness, indicating that additional interventions will be 
needed to improve retention among these subpopulations.
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Table 3.1. Study sample characteristics for patients who initiated antiretroviral 
therapy at Themba Lethu Clinic in Johannesburg, South Africa within 180 days 
before and after April 1, 2013.  
 Single-pill FDC 
regimen 
n = 465 
Multiple-pill 
regimen 
n = 659 
Overall 
 
n = 1124 
Male  
n (%) 
209 (45.0%) 278 (42.2%) 487 (43.3%) 
Age at baseline 
median (IQR) 
37.5 (31.3– 44.6) 37.4 (31.1– 45.2) 37.5 (31.1 – 44.9) 
CD4 at baseline 
median (IQR) 
171.0 (69.0 – 280.0) 158.5 (60.0 – 279.5) 164.0 (64.0 – 280.0) 
Missing 
baseline CD4 
n (%) 
24 (5.2%) 77 (11.7%) 101 (9.0%) 
Anemia at 
baseline  
n (%) 
191 (41.1%) 311 (47.2%) 502 (44.7%) 
WHO stage 
III/IV 
n (%) 
64 (13.8%) 94 (14.3%) 158 (14.1%) 
Attrition 
n (%) 
64 (13.8%) 105 (15.9%) 169 (15.0%) 
FDC = fixed dose combination; IQR = interquartile range; WHO = World Health 
Organization 
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Table 3.2. Crude and adjusted overall effect estimates of fixed-dose combination ART on attrition among patients 
who initiated ART at Themba Lethu Clinic in Johannesburg within 180 days before and after April 1, 2013. Analytic 
methods include: (A) As-treated conventional ordinary least squares linear regression, (B) Instrumental variable 
analysis, (C) Regression discontinuity, and (D) Instrumental variable analysis standardized to the clinic population 
that initiated ART after September 1, 2016. 
Method 
Unadjusted 
Risk difference 
(95% CI)* 
Adjusted for linear 
time trend 
Risk Difference 
(95% CI)* 
Adjusted for linear time trends 
and covariatesa 
Risk Difference 
(95% CI)* 
(A) As-treated conventional regressionb -0.02 (-0.06; 0.02) -0.03 (-0.10; 0.04) 0.00 (-0.08; 0.07) 
(B) Instrumental variable CACE -0.05 (-0.10; 0.00) -0.16 (-0.28; -0.04) -0.17 (-0.29; -0.05) 
(C) Regression discontinuity CACE ---c -0.16 (-0.28; -0.03) -0.17 (-0.29; -0.05) 
(D) Instrumental variable CACE standardized 
to 2016 clinic populationd 
-0.05 (-0.11; 0.00) -0.19 (-0.33; -0.05) -0.20 (-0.34; -0.05) 
a Includes terms for date, sex, age at initiation, age at initiation2, cd4 category indicators (101–200, 201–350, 350–500, 500+, missing), 
anemia, and stage indicator (1–2 versus 3–4). 
b Linear regression fit by ordinary least squares 
c Regression discontinuity analysis is inherently adjusted for time trends. 
d Standardized by inverse probability weighting 
*All 95% CIs are heteroscedasticity robust, estimated via bootstrapping with 1000 replicates 
FDC = fixed dose combination treatment; CI = confidence interval; IV = instrumental variable; CACE = Complier Average Causal Effect; 
ICSW = inverse compliance score weight; ATE = Average Treatment Effect 
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Table 3.3. Stratified crude and adjusted instrumental variable analysis of the effect of FDC antiretroviral therapy on 
one-year attrition outcomes among the study sample of individuals who initiated antiretroviral therapy at Themba 
Lethu Clinic in Johannesburg, South Africa within 180 days before and after April 1, 2013. 
 Time-adjusted  Time- and covariate-adjusteda 
  
First stageb 
Risk difference 
(95% CI)* 
Relative 
compliance 
probabilityc 
CACE 
Risk difference 
(95% CI)* 
 First stageb 
Risk difference 
(95% CI)* 
Relative 
compliance 
probabilityc 
CACE 
Risk difference 
(95% CI)* 
Overall 
 
 71.0%  
(63.2; 78.7) 
ref -0.16  
(-0.28; -0.04) 
 70.4%  
(62.8; 78.0) 
ref -0.17   
(-0.29; -0.05) 
Sex Male 72.9%  
(61.3; 84.5) 
1.03 -0.08  
(-0.26; 0.11) 
 72.5%  
(61.1; 84.0) 
1.03 -0.08  
(-0.26; 0.11) 
 
Female 69.5%  
(59.2; 79.8) 
0.98 -0.23  
(-0.39; -0.07) 
 69.2%  
(59.2; 79.2) 
0.98 -0.25  
(-0.42; -0.09) 
Anemia Yes 72.1%  
(61.2; 83.0) 
1.02 -0.09  
(-0.29; 0.11) 
 72.7%  
(62.1; 83.3) 
1.03 -0.11  
(-0.31; 0.09) 
 
No 70.2%  
(59.4; 81.0) 
0.99 -0.22  
(-0.38; -0.06) 
 66.8%  
(56.2; 77.4) 
0.95 -0.24  
(-0.41; -0.08) 
WHO 
Stage 
1–2 70.9%  
(62.6; 79.2) 
1.00 -0.19  
(-0.31; -0.06) 
 70.4%  
(62.2; 78.6) 
1.00 -0.20  
(-0.32; -0.07) 
 
3–4 72.1%  
(51.2; 92.9) 
1.02 -0.03  
(-0.39; 0.32) 
 69.8%  
(50.4; 89.2) 
0.99 -0.07  
(-0.45; 0.32) 
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Table 3.3 continued 
 Time-adjusted  Time- and covariate-adjusteda 
  
First stageb 
Risk difference 
(95% CI)* 
Relative 
compliance 
probabilityc 
CACE 
Risk difference 
(95% CI)* 
 First stageb 
Risk difference 
(95% CI)* 
Relative 
compliance 
probabilityc 
CACE 
Risk difference 
(95% CI)* 
CD4 
(cells/µL) 
0–100 67.9%  
(54.1; 81.6) 
0.96 -0.02  
(-0.27; 0.24) 
 68.7%  
(55.3; 82.0) 
0.98 0.00  
(-0.25; 0.26) 
 
101–200 89.8%  
(79.8; 99.7) 
1.26 -0.15  
(-0.34; 0.03) 
 90.3%  
(80.9; 99.7) 
1.28 -0.16  
(-0.34; 0.03) 
 
201–350 66.1%  
(50.3; 81.7) 
0.93 -0.18  
(-0.40; 0.03) 
 65.4%  
(49.8; 80.9) 
0.93 -0.20  
(-0.43; 0.03) 
 
≥ 350 54.1%  
(22.9; 85.4) 
0.76 -0.55  
(-1.65; 0.54) 
 54.6%  
(26.9; 82.2) 
0.78 -0.58  
(-1.58; 0.42) 
 
Missing 49.9%  
(23.7; 76.2) 
0.70 -0.52  
(-1.41; 0.36) 
 44.7%  
(18.0; 71.4) 
0.63 -0.87  
(-2.11; 0.38) 
Age  
(years) 
16–29 70.6%  
(55.0; 86.3) 
0.99 -0.19  
(-0.50; 0.12) 
 69.0%  
(53.8; 84.3) 
0.98 -0.16  
(-0.48; 0.16) 
 
30–39 72.8%  
(60.7; 84.8) 
1.03 -0.31  
(-0.53; -0.10) 
 72.7%  
(61.1; 84.3) 
1.03 -0.33  
(-0.55; -0.11) 
 
40–49 70.3%  
(54.9; 85.8) 
0.99 0.00  
(-0.21; 0.22) 
 67.2%  
(51.7; 82.7) 
0.95 0.00  
(-0.22; 0.22) 
 
≥ 50 66.6%  
(42.7; 90.5) 
0.94 -0.06  
(-0.35; 0.23) 
 67.4%  
(46.0; 88.8) 
0.96 -0.08  
(-0.38; 0.22) 
a Includes terms for date, sex, age at initiation, age at initiation2, cd4 category indicators (101–200, 201–350, 350+, missing), anemia, and 
stage indicator (1–2 versus 3–4). Each term was omitted from corresponding stratum-specific analysis. 
b First stage of IV analysis is the risk difference for prescription to FDC regimens associated with the guideline change. 
c Relative compliance probability = (stratum first stage / overall first stage) 
* All confidence intervals are heteroscedasticity robust. 
FDC = fixed-dose combination; CI = confidence interval; CACE = Complier Average Causal Effect; WHO = World Health Organization
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Figure 3.1. For antiretroviral therapy initiators at Themba Lethu Clinic in 
Johannesburg, South Africa: (A) Overall proportion prescribed the single-pill 
fixed-dose combination regimen by month of treatment initiation; (B) Observed 
risk of one-year attrition by month of treatment initiation. 
   
 
 
ART = antiretroviral therapy; FDC = fixed-dose combination
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CONCLUSION 
 The studies in this dissertation examined the impact of several HIV 
treatment policy reforms in South Africa on patient outcomes. Our findings can 
inform policy conversations as access to antiretroviral therapy (ART) is extended 
to a broader population, and as single-tablet fixed-dose combinations (FDC) are 
developed for a wider variety of regimens, both in South Africa and in other 
resource-limited countries.  
 Our first study evaluated the success of ART eligibility scale-up to patients 
with CD4 ≤350 cells/µL in a network of 17 primary health care clinics located in a 
primarily rural region of South Africa. Using interrupted time series methods to 
control for secular trends, we found an expected large increase in treatment 
initiation among newly-eligible patients, with an adjusted estimate of 73.0 (95% 
CI: 42.1; 103.9) additional patients initiating treatment per month after the 
treatment expansion, and a 47% (95% CI: 19; 82) decrease in time to initiation. 
Encouragingly, we saw no crowd-out of patients with CD4 counts ≤200 cells/µL, 
who would have been eligible both before and after the scale-up. Our results 
suggest that these clinics successfully engaged the newly eligible cohort of 
patients and initiated them on ART without compromising the care of patients 
with more severe disease. Several factors likely contributed to the success of 
these clinics, including a transition to nurse-initiated management of care and a 
fast-tracked ART initiation program for sicker patients. These and other 
interventions to improve clinic resource efficiency will be necessary as the HIV 
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treatment program in South Africa strives to engage all infected individuals in 
care. 
 While engagement in care through HIV testing and treatment initiation 
represent the first steps into the HIV care cascade, retention in care is of equal 
importance. Our second and third studies evaluated the impact of FDCs, 
compared to multiple-pill treatments, on retention in care. Study 2 used 
regression discontinuity analysis to estimate the immediate change in attrition 
(including mortality and loss to follow-up) resulting from the introduction of FDCs 
as standard first-line treatment. We found an 18 percentage point decrease (95% 
CI: -33.6; -2.4) in the risk of a ≥3-month gap in care during the first year on 
treatment and similar estimates for three other measures of attrition. Our findings 
suggest that FDCs can be viewed as a tool to improve retention in care, and that 
this benefit should be considered as other FDC and non-FDC regimens become 
available. 
 In study 3 we aimed to further describe the effect of FDCs on retention in 
care using stratified instrumental variable models to determine which segments 
of the patient population experienced the greatest changes in retention. We saw 
the largest effects among women (RD -0.25; 95% CI: -0.42; -0.09), non-anemic 
patients (RD -0.24; 95% CI: -0.41; -0.08), patients with low-stage clinical disease 
(RD -0.20; 95% CI: -0.32; -0.07), and those with high CD4 counts (RD -0.58; 
95% CI: -1.58; 0.42). These results suggest that healthier patients saw the 
greatest improvement in retention in care following the switch from multiple-pill to 
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single-pill regimens. An analysis standardized to the healthier post-test-and-treat 
patient population estimated a -0.20 reduction in the risk of attrition (95% CI:        
-0.33; -0.06), providing further support for this hypothesis. In an era where the 
healthiest HIV-infected patients are now being targeted for ART treatment, FDCs 
can play a large role in preventing attrition from care. Knowledge of which 
patients will benefit most from using FDCs will be important for physicians 
deciding between treatment regimens and for policymakers designing additional 
retention-focused interventions. 
 South Africa’s HIV treatment and care program has come a long way 
since its inception, with universal eligibility for free ART and continuous efforts to 
improve clinic efficiency and the patient experience. We show that a previous 
eligibility expansion successfully engaged new patients in care without crowding 
out the system, and that the introduction of FDCs led to improved retention in 
care, especially among healthier patients. These improvements in patient 
engagement and retention are strong steps toward the UNAIDS goal of 90% of 
the population knowing their HIV status, 90% of diagnosed individuals receiving 
ART, and 90% of treated patients with viral suppression by 2020 [106]. 
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APPENDICES 
Appendix 1. Monthly count of patients initiating antiretroviral therapy at Themba Lethu Clinic in Johannesburg, 
South Africa, according to type of regimen prescribed: multiple-pill versus single-pill. 
 
  
FDC = fixed-dose combination; ART = antiretroviral therapy 
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Appendix 2. Evaluating the balance in baseline covariates at the date of the policy 
change, April 1, 2013. Plots show monthly mean covariate values according to 
date of antiretroviral therapy initiation for patients who initiated HIV treatment at 
Themba Lethu Clinic in Johannesburg, South Africa. 
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ART = antiretroviral therapy; WHO = World Health Organization 
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Appendix 3. Sensitivity analysis: Comparing patterns in monthly percent of 
patients prescribed fixed-dose combination treatment in pharmacy versus clinic 
records in Themba Lethu Clinic, Johannesburg, South Africa. 
 
 
FDC = fixed-dose combination; ART = antiretroviral therapy 
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Appendix 4. McCrary density test for bunching of ART initiation at the April 1, 
2013 policy change recommending fixed-dose combination treatment as standard 
first-line ART 
 
Bin size = 9 days; bandwidth = ±160 days 
X axis value 0 = April 1, 2013 
Risk difference = 0.11 (SE 0.14), p = 0.43
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Appendix 5: Mean count of ART pickups per patient at the hospital pharmacy in 
the first year on HIV treatment at Themba Lethu Clinic in Johannesburg, South 
Africa. 
 
ART = antiretroviral therapy  
 
 
 
8
6
 
Appendix 6. (A) First stage (complier proportion), (B) Intention-to-treat, and (C) Complier average causal effect 
regression discontinuity results for all attrition outcomes, using bandwidth optimized for CACE analysis. Exposure 
for ITT is the April 1, 2013 policy change; exposure for CACE is FDC treatment compared to multiple-pill regimens. 
Outcome 
Bandwidth* 
(days) 
(A)  
First Stage 
(Complier proportion) 
Risk Difference 
(95% CI) 
(B)  
Intention-to-treat 
 
Risk Difference      
(95% CI) 
(C) 
Complier 
Average Causal 
Effect 
Risk Difference 
(95% CI) 
≥3-month lapse in care ±131.9 66.4% (57.4; 75.3) -12.0 (-22.3; -1.6) -18.0 (-33.6; -2.4) 
Disengagement from 
care in first year 
±120.5 65.2% (55.5; 74.8) -10.2 (-22.3; 1.8) -15.7 (-34.3; -2.9) 
No 6-month viral load 
monitoring 
±177.3 70.5% (62.6; 78.4) -9.8 (-20.8; 1.3) -14.2 (-29.8; 1.4) 
Insufficient ART pickup ±219.6 74.4% (67.5; 81.3) -4.6 (-9.7; 0.5) -6.1 (-12.9; 0.8) 
 
*Optimal bandwidth using Imbens-Kalyanaraman method [94] as implemented by Calonico, Cattaneo, and Titiunik [95]. 
CACE = Complier average causal effect; ITT = Intention-to-treat; FDC = Fixed-dose combination; CI = confidence interval; 
ART = antiretroviral therapy 
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Appendix 7. Comparison of linear versus logistic two-stage least squares 
regression discontinuity analysis of attrition associated with the introduction of 
fixed-dose combination ART at Themba Lethu clinic in South Africa. 
 
 
    
Bandwidth = 132 days 
Second stage uses linear first stage model 
ART = antiretroviral therapy; RDD = regression discontinuity design; FDC = fixed-dose 
combination  
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Appendix 8: Comparing characteristics for patients who initiated antiretroviral 
therapy at Themba Lethu Clinic in Johannesburg, South Africa within 180 days 
before and after April 1, 2013, versus those who initiated in the year following 
September 1, 2016. 
 
  
Initiated ART 
between Oct 2012 – 
Oct 2013 
n = 1124 
Initiated ART 
between Sept 2016 
– July 2017 
n = 755 
Male 
n (%)  
487 (43.3%) 386 (43.0%) 
Anemia at 
baseline 
n (%)  
502 (44.7%) 401 (44.7%) 
WHO stage III/IV 
n (%)  
158 (14.1%) 48 (17.7%)* 
Age at baseline 
median (IQR)  
37.5 (31.1 – 44.9) 37.0 (30.0 – 44.7) 
CD4 at baseline 
n (%) 
0 – 100 
101 – 200 
201 – 350 
351 – 500 
> 500 
missing 
354 (30.7%) 
254 (22.6%) 
324 (28.8%) 
55 (4.9%) 
45 (4.0%) 
101 (9.0%) 
219 (24.4%) 
114 (12.7%) 
165 (18.4%) 
100 (11.1%) 
176 (19.6%) 
124 (13.8%) 
 
ART = antiretroviral therapy; WHO = World Health Organization; IQR = interquartile 
range
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Appendix 9: Comparing characteristics, treatment exposure, and outcomes for patients with and without recorded 
baseline CD4 counts among the study sample of individuals who initiated antiretroviral therapy at Themba Lethu 
Clinic in Johannesburg, South Africa within 180 days before and after April 1, 2013. 
 Missing baseline 
CD4  
Recorded 
baseline CD4 
 n = 101 n = 1023 
Male  
n (%) 
53 (52.5%) 434 (42.4%) 
Age at baseline 
median (IQR) 
36.8 (31.3 – 44.3) 37.5 (31.1 – 44.9) 
Anemia at 
baseline  
n (%) 
55 (54.5%) 447 (43.7%) 
WHO stage III/IV 
n (%) 
20 (19.8%) 138 (13.5%) 
FDC treatment 
n (%) 
24 (23.8%) 441 (43.1%) 
Attrition 
n (%) 
26 (25.7%) 143 (14.0%) 
FDC = fixed dose combination; IQR = interquartile range; WHO = World Health Organization 
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Appendix 10: Comparing characteristics for patients according to instrumental variable subtypes (described below), 
among the study sample of individuals who initiated antiretroviral therapy at Themba Lethu Clinic in Johannesburg, 
South Africa within 180 days before and after April 1, 2013. 
 180 days before policy change  180 days after policy change 
 
Always-takers 
(FDC) 
Compliers +  
never-takers 
(Multiple pills)  
Never-takers 
(Multiple pills) 
Compliers +  
always-takers 
(FDC) 
 
n = 15  
(2.5%) 
n = 584 
(97.5%) 
 n = 75 
(14.3%) 
n = 450 
(85.7%) 
Male  
(n, %) 
5 (33.3%) 247 (42.3%) 
 
31 (41.3%) 204 (45.3%) 
Age at initiation 
(median, IQR) 
40.6 (31.6 – 43.7) 37.6 (31.1 – 45.1) 
 
35.8 (30.8 – 45.9) 37.3 (31.2 – 44.7) 
CD4 at baseline  
(median, IQR) 
318.0 (212.0 – 624.0) 169.0 (67.0 – 283.0) 
 
99.0 (19.0 – 335.0) 169.5 (70.0 – 279.0) 
Missing CD4 at baseline 
(n, %) 
0 (0.0%) 57 (9.8%) 
 
20 (26.7%) 24 (5.3%) 
Anemia at baseline  
(n, %) 
2 (13.3%) 269 (46.1%) 
 
42 (56.0%) 189 (42.0%) 
WHO Stage ≥3  
(n, %) 
2 (13.3%) 80 (13.7%) 
 
14 (18.7%) 62 (13.8%) 
Patients on FDC while multiple-pill ART was the recommended treatment are identifiable “always-takers.” 
Patients on multiple-pill ART while multiple-pill ART was the recommended treatment are either “never-takers” or “compliers.” 
Patients on multiple-pill ART while FDC was the recommended treatment are identifiable “never-takers.” 
Patients on FDC while FDC was the recommended treatment are either “always-takers” or “compliers.” 
FDC = fixed-dose combination; ART = antiretroviral therapy; IQR = interquartile range; WHO = World Health Organization 
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Appendix 11. Comparison of linear versus logistic two-stage least squares 
instrumental variable analysis of attrition associated with the introduction of 
fixed-dose combination ART at Themba Lethu clinic in South Africa. 
 
 
    
Bandwidth = 180 days 
Second stage uses linear first stage model 
ART = antiretroviral therapy; FDC = fixed-dose combination   
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Appendix 12. Observed attrition among the study sample of individuals who 
initiated antiretroviral therapy at Themba Lethu Clinic in Johannesburg, South 
Africa within 180 days before and after April 1, 2013, stratified by patient 
characteristics. 
 Observed risk of attrition 
 
Overall 
n = 1124 
Before            
April 1, 2013 
(-180 days) 
n = 659 
After           
April 1, 2013 
(+180 days) 
n = 465 
Crude risk 
difference 
Sex 
Male 
Female 
 
363 (19.6%) 
384 (14.5%) 
 
253 (20.8%) 
293 (15.8%) 
 
110 (17.2%) 
91 (11.6%) 
 
-3.5 (-7.3; 0.1) 
-4.2 (-6.9; -1.4) 
Anemia 
Y 
N 
 
471 (21.8%) 
276 (11.8%) 
 
346 (23.2%) 
200 (12.6%) 
 
125 (18.7%) 
76 (10.1%) 
 
-4.5 (-8.2; -0.8) 
-2.5 (-5.2; 0.2) 
WHO stage 
1–2 
3–4 
 
597 (15.5%) 
150 (23.0%) 
 
440 (16.7%) 
106 (24.1%) 
 
157 (13.0%) 
44 (20.7%) 
 
-3.7 (-6.1; -1.4) 
-3.4 (-10.2; 3.3) 
CD4 category 
0–100 
101–200 
201–350 
≥350 
Missing 
 
292 (22.3%) 
145 (14.5%) 
136 (9.4%) 
43 (13.4%) 
131 (31.0%) 
 
198 (23.4%) 
109 (15.7%) 
108 (9.8%) 
29 (16.4%) 
102 (38.9%) 
 
94 (20.2%) 
36 (11.8%) 
28 (8.1%) 
14 (9.8%) 
29 (18.0%) 
 
-3.2 (-7.8; 1.4) 
-3.9 (-8.5; 0.6) 
-1.8 (-5.2; 1.6) 
-6.6 (-13.9; 0.7) 
-20.9 (-29.3; -12.5) 
Age category 
16–29 
30–39 
40–49 
50+ 
 
173 (20.5%) 
300 (16.8%) 
187 (15.0%) 
87 (14.0%) 
 
129 (22.3%) 
221 (18.0%) 
133 (15.4%) 
63 (15.4%) 
 
44 (16.5%) 
79 (14.1%) 
54 (14.1%) 
24 (11.3%) 
 
-5.8 (-11.4; -0.2) 
-3.9 (-7.5; -0.3) 
-1.3 (-5.6; 2.9) 
-4.1 (-9.6; 1.4) 
WHO = World Health Organization
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Appendix 13. Stratified crude and adjusted analyses of the effect of FDCs on one-year attrition among individuals 
who initiated ART at Themba Lethu Clinic in South Africa within 180 days before and after April 1, 2013 using (A) 
Instrumental variable, (B) As-treated ordinary least squares, and (C) Regression discontinuity analyses. 
  (A) Instrumental Variable (B) Ordinary Least Squares (C) Regression Discontinuity 
  
 
Time-adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
Time-
adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
Time-
adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
Overall  -0.16  
(-0.28; -0.04) 
-0.17  
(-0.29; -0.05) 
-0.03  
(-0.10; 0.04) 
0.00  
(-0.08; 0.07) 
-0.16  
(-0.28; -0.03) 
-0.17  
(-0.29; -0.05) 
Sex Male 
 
Female 
-0.08  
(-0.26; 0.11) 
-0.23  
(-0.39; -0.07) 
-0.08  
(-0.26; 0.11) 
-0.25  
(-0.42; -0.09) 
0.05  
(-0.06; 0.16) 
-0.09  
(-0.18; 0.00) 
0.08  
(-0.03; 0.20) 
-0.08  
(-0.17; 0.02) 
-0.07  
(-0.26; 0.11) 
-0.22  
(-0.38; -0.06) 
-0.08  
(-0.25; 0.10) 
-0.25  
(-0.41; -0.09) 
Anemia Yes 
 
No 
-0.09  
(-0.29; 0.11) 
-0.22  
(-0.38; -0.06) 
-0.11  
(-0.31; 0.09) 
-0.24  
(-0.41; -0.08) 
0.02  
(-0.09; 0.12) 
-0.05  
(-0.14; 0.04) 
0.02  
(-0.09; 0.12) 
-0.03  
(-0.13; 0.07) 
-0.09  
(-0.31; 0.13) 
-0.21  
(-0.36; -0.06) 
-0.10  
(-0.29; 0.09) 
-0.23  
(-0.38; -0.07) 
WHO 
stage 
1–2 
 
3–4 
-0.19  
(-0.31; -0.06) 
-0.03  
(-0.39; 0.32) 
-0.20  
(-0.32; -0.07) 
-0.07  
(-0.45; 0.32) 
-0.03  
(-0.11; 0.04) 
-0.01  
(-0.17; 0.15) 
0.00  
(-0.08; 0.07) 
0.02  
(-0.17; 0.20) 
-0.18  
(-0.31; -0.05) 
-0.03  
(-0.36; 0.29) 
-0.19  
(-0.32; -0.07) 
-0.05  
(-0.39; 0.30) 
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Appendix 13, continued. 
*Controlling for date, sex, age at initiation, age at initiation2, cd4 category indicators (101–200, 201–350, 350+, missing), anemia, and 
stage indicator (1–2 versus 3–4). 
**CI = confidence interval. All confidence intervals are heteroscedasticity adjusted. 
  
  (A) Instrumental Variable (B) Ordinary Least Squares (C) Regression Discontinuity 
  
 
Time-adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
Time-adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
Time-adjusted 
Risk difference 
(95% CI)** 
Time and 
covariate-
adjusted* 
Risk difference 
(95% CI)** 
CD4 
(cells/µL) 
0–100 
 
101–200 
 
201–350 
 
≥ 350 
 
Missing 
-0.02  
(-0.27; 0.24) 
-0.15  
(-0.34; 0.03) 
-0.18  
(-0.40; 0.03) 
-0.55  
(-1.65; 0.54) 
-0.52  
(-1.41; 0.36) 
0.00  
(-0.25; 0.26) 
-0.16  
(-0.34; 0.03) 
-0.20  
(-0.43; 0.03) 
-0.58  
(-1.58; 0.42) 
-0.87  
(-2.11; 0.38) 
0.04  
(-0.09; 0.17) 
-0.22  
(-0.39; -0.05) 
-0.04  
(-0.16; 0.09) 
0.03 
(-0.17; 0.22) 
0.12  
(-0.08; 0.32) 
0.05  
(-0.08; 0.19) 
-0.21  
(-0.38; -0.05) 
-0.04  
(-0.17; 0.08) 
0.05  
(-0.16; 0.25) 
0.05  
(-0.15; 0.24) 
-0.01  
(-0.27; 0.24) 
-0.13  
(-0.31; 0.04) 
-0.18  
(-0.38; 0.01) 
-0.50  
(-1.16; 0.17) 
-0.43  
(-1.19; 0.34) 
0.01  
(-0.24; 0.25) 
-0.14  
(-0.31; 0.03) 
-0.20  
(-0.39; 0.00) 
-0.53  
(-1.20; 0.14) 
-0.71  
(-1.62; 0.20) 
Age  
(years) 
16–29 
 
30–39 
 
40–49 
 
≥ 50 
-0.19  
(-0.50; 0.12) 
-0.31 
(-0.53; -0.10) 
0.00  
(-0.21; 0.22) 
-0.06  
(-0.35; 0.23) 
-0.16  
(-0.48; 0.16) 
-0.33  
(-0.55; -0.11) 
0.00  
(-0.22; 0.22) 
-0.08  
(-0.38; 0.22) 
-0.14  
(-0.29; 0.02) 
-0.09  
(-0.22; 0.03) 
0.08  
(-0.05; 0.22) 
0.06  
(-0.05; 0.16) 
-0.05  
(-0.23; 0.13) 
-0.07  
(-0.20; 0.06) 
0.12  
(-0.03; 0.26) 
0.04  
(-0.09; 0.16) 
-0.17  
(-0.48; 0.13) 
-0.31  
(-0.52; -0.10) 
-0.01  
(-0.22; 0.20) 
-0.04  
(-0.30; 0.21) 
-0.18  
(-0.48; 0.12) 
-0.31  
(-0.52; -0.11) 
-0.01  
(-0.23; 0.20) 
-0.08  
(-0.34; 0.18) 
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